

Dave L. Dixon, Pharm.D., FACC, FAHA, FCCP, FNLA, BCACP, CLS

Updated: 11/19/2023

Nancy L. and Ronald H. McFarlane Professor (*Tenured*) of Pharmacy
Chair, Department of Pharmacotherapy & Outcomes Science
Virginia Commonwealth University (VCU) School of Pharmacy

Address: 410 N. 12th St., Box 980533, Richmond, VA, 23298-0533 | **Phone:** (804) 628-3784 | **E-mail:** dldixon@vcu.edu

[VCU Directory](#) | [PubMed](#) | [Web of Science Researcher Profile](#) | [Google Scholar Profile](#) | [Scopus Author Profile](#)

EDUCATION & POST-DOCTORAL TRAINING

| | |
|--|-----------|
| VCU Department Chair Certification Program, Grace E. Harris Leadership Institute, Richmond, VA | July 2021 |
| VCU Leadership Program, Grace E. Harris Leadership Institute, Richmond, VA | 2015-2016 |
| PGY-1 Primary Care Residency, Charles George VA Medical Center, Asheville, NC | 2006-2007 |
| Doctor of Pharmacy, Campbell University College of Pharmacy & Health Sciences, Buies Creek, NC | 2002-2006 |
| Pre-Pharmacy Coursework, Campbell University, Buies Creek, NC | 1999-2002 |

PROFESSIONAL EXPERIENCE

Administrative Appointments

| | |
|---|--------------------|
| Chair, Department of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy | Nov 2021-Present |
| Interim Chair, Department of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy | June 2021-Oct 2021 |
| Director, Center for Pharmacy Practice Innovation, VCU School of Pharmacy | May 2017-Dec 2021 |
| Interim Director, Center for Pharmacy Practice Innovation, VCU School of Pharmacy | Aug 2016-Apr 2017 |
| Vice-Chair of Clinical Services, Department of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy | Aug 2015-June 2021 |

Faculty Appointments

| | |
|---|---------------------|
| Endowed Professorship, Nancy L. and Ronald H. McFarlane Professor of Pharmacy, VCU School of Pharmacy | Jan 2022-Present |
| Tenured Professor Department of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy | July 2022-Present |
| Associate Professor (University-approved switch to tenure-eligible track) Department of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy | July 2019-June 2022 |
| Associate Professor (term) Department of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy | July 2016-June 2019 |
| Assistant Professor (term) Department of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy | Jan 2012-June 2016 |

Affiliate Faculty Appointments

| | |
|--|------------------|
| Professor Department of Kinesiology and Health Sciences, VCU College of Humanities and Sciences | Jan 2023-Present |
|--|------------------|

| | |
|---|-------------------|
| Professor Department of Internal Medicine (Division of Cardiology), VCU School of Medicine | Sept 2022-Present |
| Professor College of Pharmacy, Gulf Medical University, United Arab Emirates | Oct 2021-Present |
| Graduate Faculty Department of Pharmacotherapy & Outcomes Science, VCU School of Pharmacy | May 2019-Present |
| Core Faculty Center for Pharmacy Practice Innovation, VCU School of Pharmacy | Oct 2015-Present |

Clinical Experience

| | |
|--|---------------------|
| Ambulatory Care Pharmacist (Preventive Cardiology), VCU Health, Richmond, VA | July 2012-Present |
| Ambulatory Care Pharmacist, Center for Healthy Hearts (free clinic), Richmond, VA | Jan 2012- June 2019 |
| Clinical Pharmacist Practitioner, Atrium Health Wake Forest Baptist, Winston-Salem, NC | Aug 2007-Oct 2011 |

HONORS and AWARDS

| | |
|---|------|
| Achievement Award, ACCP Ambulatory Care Practice & Research Network | 2023 |
| Clinical Practice Award, ACCP Cardiology Practice & Research Network | 2022 |
| Excellence in Service Award, VCU School of Pharmacy | 2021 |
| Fellow, American Heart Association (FAHA) | 2021 |
| Outstanding Reviewer, <i>Journal of the American College of Clinical Pharmacy</i> | 2020 |
| Publons Peer Review Award, Top 1% of reviewers in Pharmacology and Toxicology | 2018 |
| Outstanding Reviewer, <i>Pharmacotherapy</i> | 2018 |
| President's Service Award, Southeast Regional Chapter, National Lipid Association | 2018 |
| Fellow, American College of Cardiology (FACC) | 2017 |
| Fellow, American College of Clinical Pharmacy (FCCP) | 2016 |
| Member Recognition Award, ACCP Ambulatory Care Practice & Research Network | 2016 |
| Alumni Spotlight, Campbell University College of Pharmacy Alumni Association | 2016 |
| Outstanding Contribution in Reviewing, <i>Journal of Clinical Lipidology</i> | 2015 |
| Fellow, National Lipid Association (FNLA) | 2014 |
| Innovations in Teaching Award, American Association of Colleges of Pharmacy | 2014 |
| Outstanding Preceptor Award, VCU School of Pharmacy Class of 2013 | 2013 |
| Interprofessional Education Collaborative Development Award, Association of American Medical Colleges | 2013 |
| Registration Scholarship Award, Association of Diabetes Care & Education Specialists | 2013 |
| Phi Lambda Sigma Pharmacy Leadership Society, <i>Alpha Zeta</i> | 2003 |

RESEARCH FUNDING

Completed Grants

| | | | | |
|--|---|---------------------------------|-----------|-----------------------|
| Translation of Evidence-Based Diabetes Care into Clinical Practice Across a Large Medical Group | Boehringer Ingelheim (investigator-initiated) | Role: PI | \$200,813 | Apr 2022- Mar 2023 |
| Medical oncologists' knowledge, comfort level, and ownership of the responsibility for managing hyperglycemia in cancer patients undergoing chemotherapy | American Association of Colleges of Pharmacy New Investigator Award | Role: Co-I (PI: Teresa Salgado) | \$10,000 | Mar 2022- Feb 2023 |

| | | | | |
|--|--|--|-------------|-------------------------|
| Virginia Medicaid MCO Value-Based Payment Pilot for the National Diabetes Prevention Program | Virginia Department of Health | Role: PI | \$32,500 | Sept 2021- June 2023 |
| A multifaceted adaptive mobile application to promote self-management and improve outcomes in heart failure | NIH (NIA): R01AG062582 | Role: Site PI (PI: Michael Dorsch) | \$35,569 | Apr 2020- Apr 2023 |
| Interprofessional Strategies to Improve Diabetes & Cardiovascular Disease in Underserved Areas | Virginia Department of Health (CDC-RFA-DP-18-1817) | Role: PI | \$1,262,290 | Oct 2018- Sept 2023 |
| <i>Press Coverage:</i> VCU News. With \$1.3M grant, VCU to expand community treatment of diabetes and hypertension. L. Small and G. Weatherford. March 13, 2019. | | | | |
| Effects of Interleukin-1 Blockade on Exercise Capacity in Patients with Recently Decompensated Systolic Heart Failure | NIH (NHLBI): R61HL139943 | Role: Co-I (PI: Ben Van Tassell) | \$2,700,048 | July 2018- June 2023 |
| Using 24-hour ambulatory blood pressure monitoring (ABPM) to examine association between blood pressure phenotypes and cognitive impairment among African Americans | Center for Healthy Aging Behaviors and Longitudinal Investigations Pilot | Role: Co-PI | \$22,973 | July 2021- June 2022 |
| The association of ambulatory blood pressure phenotypes with cognition in community-dwelling older adults: A pilot study | VCU CCTR Endowment Fund CTSA UL1TR002649 | Role: Co-PI | \$49,782 | Feb 2021- July 2022 |
| Factors affecting job satisfaction in board-certified pharmacists | Board of Pharmacy Specialties Seed Grant | Role: Co-I (PI: Lauren Pamulapati) | \$5,000 | Nov 2020- Nov 2022 |
| Implementation and Evaluation of a 24-hour Ambulatory Blood Pressure Monitoring Service in Community Pharmacies | Community Pharmacy Foundation Grant #71756 | Role: PI | \$47,165 | Feb 2019- Feb 2020 |
| A Pharmacist-driven Continuous Glucose Monitoring Program for Diabetes Management in an Uninsured Population | Virginia Pharmacists Association Foundation | Role: Co-I (PI: Jamie Cook) | \$2,500 | Jan 2017- Dec 2019 |
| Unsaturated Fatty Acids Enriched Diet to Improve Cardiorespiratory Fitness in Obese Patients: A Feasibility Study | VCU Department of Internal Medicine Pilot Project Grant Program | Role: Co-I (PI: Salvatore Carbone) | \$20,000 | Jan 2017- Dec 2018 |
| Treatment of Diabetes in Patients with Systolic Heart Failure: Canagliflozin versus Sitagliptin | Janssen Therapeutics (investigator-initiated) | Role: Co-I (PI: Antonio Abbate) | \$809,347 | Oct 2016- Oct 2018 |
| Primary Care Training Collaborative Educational Program: A Retooling Program for the Future | Martin Health Foundation | Role: Co-PI | \$99,749 | Mar 2015- Mar 2019 |
| An Interprofessional Intervention with Behavioral Health and Pharmacy Trainees to Reduce Smoking Rates in a Latino Population at a Free Health Clinic | VCU Community Engagement Grant | Role: Co-I (PI: John Bucheit) | \$17,224 | Jan 2017- Jan 2019 |

| | | | | |
|--|---|------------------------------------|-----------|------------------------|
| SGLT2 Inhibitors in Diabetic Patients with Heart Failure with Reduced Ejection Fraction | AHA Mentored Clinical and Population Research | Role: Co-I (PI: Salvatore Carbone) | \$154,000 | Jan 2016- Jan 2018 |
| Impact of a Diabetes Prevention Program Provided by Pharmacists in a Collaborative Practice | Virginia Pharmacists Association Foundation | Role: Co-I (PI: Lauren Caldas) | \$2,500 | Jan 2015- Jan 2017 |
| Interleukin-1 Blockade in Heart Failure with Preserved Ejection Fraction (DHART2) | NIH (NHLBI): R34HL118348 | Role: Co-I (PI: Antonio Abbate) | \$681,103 | Jan 2014- Jan 2016 |
| Clinical Pharmacist Understanding of the 2013 ACC/AHA Cholesterol Guideline | ACCP Cardiology PRN Seed Grant | Role: Co-I (PI: John Buchet) | \$5,000 | Oct 2016- Sept 2017 |
| Nighttime Dosing of Amlodipine versus Lisinopril in Non-Dipping African Americans | American Association of Colleges of Pharmacy New Investigator Award | Role: PI | \$10,000 | 2015- 2016 |
| iForum Rx: An Online Journal Club for Ambulatory Care Practitioners | ACCP Ambulatory Care PRN Innovation Grant | Role: Co-I (PI: Stuart Haines) | \$2,000 | 2013- 2014 |
| Use of Video Recorded Clinic Visits to Improve Assessment of Student Pharmacist Clinical Interviewing Skills | VCU Center for Teaching Excellence Small Grant Program | Role: PI | \$800 | 2012- 2013 |

PEER-REVIEWED PUBLICATIONS (*co-first or co-senior author, **mentee)

140. Sargent L, Zimmerman KM, Mohammed A, Barrett MJ, Nawaz H, Wyman-Chick K, Mackiewicz M, Roman Y, Slattum P, Russell S, **Dixon DL**, Lageman SK, Hobgood S, Thacker LR, Price ET. Low-Income Older Adults' Vulnerability to Anticholinergic Medication-Associated Frailty. *Drugs Aging*. 2023 Oct 19. doi: 10.1007/s40266-023-01069-7. Epub ahead of print. PMID: 37856064.

139. Mehta A, Lee TB, Alebna P, Grandhi GR, **Dixon DL**, Salloum FN, Sanyal AJ, Siddiqui MS. Discordant association of nonalcoholic fatty liver disease with lipoprotein(a) and markers of atherogenic dyslipidemia. *J Clin Lipidol*. 2023 Sep 21:S1933-2874(23)00262-3. doi: 10.1016/j.jacl.2023.09.003. Epub ahead of print. PMID: 37957050.

138. **Dixon DL**, Johnston K, Patterson J, Marra CA, Tsuyuki RT. Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States. *JAMA Netw Open*. 2023 Nov 1;6(11):e2341408. doi: 10.1001/jamanetworkopen.2023.41408. PMID: 37921763.

Press Coverage:

- VCU News. [Expanding pharmacists' role for patients with hypertension could prevent 15 million heart attacks and save \\$1.1 trillion over 30 years, VCU-led study finds](#). MK Brogan. November 3, 2023
- VCU Health News Center. [VCU-led study is among first to explore the economics of how pharmacists can help improve blood pressure control](#). MK Brogan. November 3, 2023.
- Complete press coverage can be found here: <https://jamanetwork.altmetric.com/details/156087517/news>

137. Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, **Dixon DL**, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA

Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2023 Aug 29;148(9):e9-e119. doi: 10.1161/CIR.0000000000001168. Epub 2023 Jul 20. PMID: 37471501, *J Am Coll Cardiol*. 2023 Aug 29;82(9):833-955. doi: 10.1016/j.jacc.2023.04.003. Epub 2023 Jul 20. PMID: 37480922.

136. **Dixon DL**. Is the “Clinical Pharmacist” Designation Still Relevant? *J Am Coll Clin Pharm*. 2023;6:672–674. doi: 10.1002/jac5.1835

135. ****Alhomoud IS, Talasaz A, Mehta A, Kelly M, Sisson EM, Bucheit JD, Brown R, Dixon DL**. Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease: A Review of Current and Emerging Therapies. *Pharmacotherapy*. 2023 Jul 18. doi: 10.1002/phar.2851. Epub ahead of print. PMID: 37464942. **[Invited Review]**

134. Romeo FJ, Del Buono MG, Aguilar-Gallardo JS, Lorente-Ros M, Damonte JI, Chiabrando JG, **Dixon DL**, Biondi-Zoccai G, Abbate A, Carbone S. Cardiac remodeling with SGLT2 inhibitors in heart failure with reduced ejection fraction. *Minerva Cardiol Angiol*. 2023 Jun 13. doi: 10.23736/S2724-5683.22.06207-X. Epub ahead of print. PMID: 37310155.

133. ****Cutrell S, Alhomoud IS, Mehta A, Talasaz AH, Van Tassell B, Dixon DL**. ACE-Inhibitors in Hypertension: A Historical Perspective and Current Insights. *Curr Hypertens Rep*. 2023 Jun 7. doi: 10.1007/s11906-023-01248-2. Epub ahead of print. PMID: 37284934. **[Invited Review]**

132. Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, **Dixon DL**, Januzzi JL Jr, Yancy CW. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2023 May 9;81(18):1835-1878. doi: 10.1016/j.jacc.2023.03.393. Epub 2023 Apr 19. PMID: 37137593.

131. Moroni F, Ayers MP, **Dixon DL**, Abbate A. Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome. *J Cardiovasc Pharmacol*. 2023 May 1;81(5):336-338. doi: 10.1097/FJC.0000000000001411. PMID: 37043382. **[Invited Editorial]**

130. Agarwala A, Satish P, Al Rifai M, Mehta A, Cainzos-Achirica M, Shah NS, Kanaya AM, Sharma GV, **Dixon DL**, Blumenthal RS, Natarajan P, Nasir K, Virani SS, Patel J. Identification and Management of Atherosclerotic Cardiovascular Disease Risk in South Asian Populations in the U.S. *JACC Adv*. 2023 Mar;2(2):100258. <https://doi.org/10.1016/j.jacadv.2023.100258>

129. Mehta A, ***Dixon DL**, Saeed A, Kelly MS, Gulati M, Shapiro MD, Sperling LS, Virani SS. With Current Safety and Efficacy Data, Should Statins Be Made Available as Nonprescription Over-the-Counter Drugs? *Curr Cardiol Rep*. 2023 May;25(5):423-430. doi: 10.1007/s11886-023-01861-2. Epub 2023 Mar 27. PMID: 36971960.

128. Virani SS, Aspary K, **Dixon DL**, Ferdinand KC, Heidenreich PA, Jackson EJ, Jacobson TA, McAlister JL, Neff DR, Gulati M, Ballantyne CM. The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. *J Clin Lipidol*. 2023 Mar-Apr;17(2):208-218. doi: 10.1016/j.jacl.2023.02.003. Epub 2023 Feb 27. PMID: 36965958, *Am J Prev Cardiol*. 2023 Feb 27;13:100472. doi: 10.1016/j.ajpc.2023.100472. PMID: 36970638

127. Talasaz A, Sculthorpe R, Pak M, Lipinski M, Roberts C, Markley R, Trankle C, Canada JM, Wohlford GF, Golino M, **Dixon DL**, Van Tassell B, Abbate A. Comparison of safety and biological efficacy of anakinra (Kineret®) dispensed in polycarbonate plastic versus borosilicate glass syringes: a patient-level analysis of VCUART2 and VCUART3 clinical trials. *J Pharmacol Exp Ther*. 2023 Mar 3;JPET-AR-2022-001404. doi: 10.1124/jpet.122.001404. Epub ahead of print. PMID: 36868827.

126. Tawfik YMK, Van Tassell BW, **Dixon DL**, Baker WL, Fanikos J, Buckley LF. Effects of Intensive Systolic Blood Pressure Lowering on End-Stage Kidney Disease and Kidney Function Decline in Adults With Type 2 Diabetes Mellitus and Cardiovascular Risk Factors: A Post Hoc Analysis of ACCORD-BP and SPRINT. *Diabetes Care*. 2023 Apr 1;46(4):868-873. doi: 10.2337/dc22-2040. PMID: 36787937.

125. Kakavand H, Aghakouchakzadeh M, Shahi A, Virani SS, **Dixon DL**, Van Tassell BW, Talasaz AH. A stepwise approach to prescribing novel lipid-lowering medications. *J Clin Lipidol*. 2022 Nov-Dec;16(6):822-832. doi: 10.1016/j.jacl.2022.10.003. Epub 2022 Oct 19. PMID: 36522804.

124. **Dixon DL**, Harris IM, Aljadeed R, Anderson KC, Aycock A, Beavers C, Beckman EJ, Isaacs D, McCoy E, Sandler A, Saseen JJ, Singh S, Wagner J. Overview of Clinical Practice Guideline Development, Application to Pharmacy Practice, and Roles for Pharmacists. *J Am Coll Clin Pharm*. 2023;6(1):73-84. doi:10.1002/jac5.1743. [White Paper]

Press Coverage: Featured on ACCP Journals Podcast. [Episode 97: Clinical Practice Guidelines](#). J. Bauman. Februar 13, 2023.

123. **Dixon DL**. The impact of PCSK9 modulation on cardiovascular outcomes: recent advances and the managed care implications. *Am J Manag Care*. 2022 Sep;28(8 Suppl):S139-S147. doi: 10.37765/ajmc.2022.89269. PMID: 36493346. [Invited Review]

122. Buckley LF, Baker WL, Van Tassell BW, Cohen JB, Alkhezi O, Bress AP, **Dixon DL**. Systolic Blood Pressure Time in Target Range and Major Adverse Kidney and Cardiovascular Events. *Hypertension*. 2023 Feb;80(2):305-313. doi: 10.1161/HYPERTENSIONAHA.122.20141. Epub 2022 Oct 18. PMID: 36254738.

Editorial: Schlaich MP. Time in Target Range: The Future of Assessing Adequacy of Blood Pressure Control? *Hypertension*. 2023 Feb;80(2):314-315. doi: 10.1161/HYPERTENSIONAHA.122.20355. Epub 2023 Jan 18. PMID: 36652530.

121. Warden BA, Guyton JR, Kovacs AC, Durham JA, Jones LK, **Dixon DL**, Jacobson TA, Duell PB. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. *J Clin Lipidol*. 2023 Jan-Feb;17(1):19-39. doi:10.1016/j.jacl.2022.09.001. Epub 2022 Sep 11. PMID: 36115813.

120. Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, **Dixon DL**, Maki KC. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. *J Clin Lipidol*. 2022 Jul-Aug;16(4):361-375. doi: 10.1016/j.jacl.2022.05.068. Epub 2022 Jun 9. PMID: 35718660.

119. Van Tassell B, Mihalick V, Thomas G, Marawan A, Talasaz AH, Lu J, Kang L, Ladd A, Damonte JI, **Dixon DL**, Markley R, Turlington J, Federmann E, Del Buono MG, Biondi-Zoccai G, Canada JM, Arena R, Abbate A. Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study. *J Transl Med*. 2022 Jun 15;20(1):270. doi: 10.1186/s12967-022-03466-9. PMID: 35706006.

118. **Dixon DL**, Patel J, Spence R, Talasaz AH, Abbate A, Wiggins BS. Select drug-drug interactions with colchicine and cardiovascular medications: A review. *Am Heart J*. 2022 Oct;252:42-50. doi: 10.1016/j.ahj.2022.06.002. Epub 2022 Jun 14. PMID: 35714680.

117. ****Tran C**, Vo V, Taylor P, Koehn DA, Virani SS, **Dixon DL**. Adherence to lipid monitoring and its impact on treatment intensification of LDL-C lowering therapies at an urban academic medical center. *J Clin Lipidol*. 2022 Jul-Aug;16(4):491-497. doi: 10.1016/j.jacl.2022.05.003. Epub 2022 May 11. PMID: 35610140.

116. ****Spence R**, Sisson EM, **Dixon DL**. Survey of CDC-recognized community pharmacies providing the National Diabetes Prevention Program and impact of the COVID-19 pandemic on program delivery. *J Am Pharm Assoc* (2003). 2022 Sep-Oct;62(5):1581-1586. doi: 10.1016/j.japh.2022.03.020. Epub 2022 Mar 31. PMID: 35461779; PMCID: PMC8968123.

115. Billingsley HE, Canada JM, **Dixon DL**, Kirkman DL, Bohmke N, Rotelli B, Kadariya D, Markley R, Van Tassell BW, Celi FS, Abbate A, Carbone S. Midpoint of energy intake, non-fasting time and cardiorespiratory fitness in heart failure with preserved ejection fraction and obesity. *Int J Cardiol*. 2022 May 15;355:23-27. doi: 10.1016/j.ijcard.2022.03.010. Epub 2022 Mar 9. PMID: 35276244

114. Radwan RM, Bentley JP, Patterson JA, **Dixon DL**, Salgado TM. Predictors of job satisfaction among pharmacists: A regional workforce survey. *Explor Res Clin Soc Pharm*. 2022 Mar 7;5:100124. doi: 10.1016/j.rcsop.2022.100124. PMID: 35478529.
113. Billingsley H, **Dixon D**, Yehya A, Carbone S, Abbate A. Sleeve Gastrectomy Reduces BMI and Pill Count in Patients With LVAD. *J Cardiovasc Pharmacol*. 2022 May 1;79(5):644-645. doi: 10.1097/FJC.0000000000001249. PMID: 35234737.
112. Jay JS, Ijioma SC, Holdford DA, **Dixon DL**, Sisson EM, Patterson JA. The cost-effectiveness of pharmacist-physician collaborative care models vs usual care on time in target systolic blood pressure range in patients with hypertension: a payer perspective. *J Manag Care Spec Pharm*. 2021 Dec;27(12):1680-1690. doi: 10.18553/jmcp.2021.27.12.1680. PMID: 34818090.
111. Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, Kakavand H, Ariannejad H, Gupta A, Madhavan MV, Van Tassell BW, Jimenez D, Monreal M, Vaduganathan M, Fanikos J, **Dixon DL**, Piazza G, Parikh SA, Bhatt DL, Lip GYH, Stone GW, Krumholz HM, Libby P, Goldhaber SZ, Bikdeli B. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2021 Oct 19;78(16):1635-1654. doi: 10.1016/j.jacc.2021.08.021. PMID: 34649702
110. Zheutlin AR, Derington CG, King JB, Berchie RO, Herrick JS, **Dixon DL**, Cohen JB, Shimbo D, Kronish IM, Saseen JJ, Muntner P, Moran AE, Bress AP. Factors associated with antihypertensive monotherapy among US adults with treated hypertension and uncontrolled blood pressure overall and by race/ethnicity, National Health and Nutrition Examination Survey 2013-2018. *Am Heart J*. 2022 Jun;248:150-159. doi: 10.1016/j.ahj.2021.10.184. Epub 2021 Oct 16. PMID: 34662571
109. Talasaz AH, Ho AJ, Bhatti F, Koenig RA, **Dixon DL**, Baker WL, Van Tassell BW. Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. *Pharmacotherapy*. 2021 Dec;41(12):1009-1023. doi: 10.1002/phar.2635. Epub 2021 Oct 30. PMID: 34657313.

Recognition: Top cited paper of 2021-2022 for *Pharmacotherapy* journal

108. **Dixon DL**, Baker WL, Buckley LF, Salgado TM, Van Tassell BW, Carter BL. Effect of a Physician/Pharmacist Collaborative Care Model on Time in Target Range for Systolic Blood Pressure: Post Hoc Analysis of the CAPTION Trial. *Hypertension*. 2021 Sep;78(4):966-972. doi: 10.1161/HYPERTENSIONAHA.121.17873. Epub 2021 Aug 15. PMID: 34397278.
107. Barry AR, **Dixon DL**. Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease. *Pharmacotherapy*. 2021 Dec;41(12):1056-1065. doi: 10.1002/phar.2615. Epub 2021 Aug 30. PMID: 34431129.

Recognition: Top cited paper of 2021-2022 for *Pharmacotherapy* journal

106. Shrestha DB, Budhathoki P, Sedhai YR, Baniya R, Cable CA, Kashiouris MG, **Dixon DL**, Kidd JM, Adhikari Y, Marasini A, Bhandari S. Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis. *Curr Ther Res Clin Exp*. 2021 Jul 5;95:100635. doi: 10.1016/j.curtheres.2021.100635. PMID: 34367383
105. **Dixon DL**, Baker WL. Long-term Association of Altmetric Attention Scores With Citations in Selected Major Pharmacy Journals. *Am J Pharm Educ*. 2022 Feb;86(2):ajpe8606. doi: 10.5688/ajpe8606. Epub 2021 Jul 22. PMID: 34301563.
104. **Dixon DL**, Billingsley HE, Canada JM, Trankle CR, Kadariya D, Cooke R, Hart L, Van Tassell B, Abbate A, Carbone S. Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study. *J Cardiovasc Pharmacol*. 2021 Sep 1;78(3):407-410. doi: 10.1097/FJC.0000000000001083. PMID: 34132690
103. **Dixon DL**, Sobieraj DM, Brown RE, Koenig RA, Wagner M, Baker WL. A Bibliometric Analysis of Peer-Reviewed Journal Publications of Pharmacy Practice Department Chairs. *Am J Pharm Educ*. 2021 Sep;85(8):8481. doi: 10.5688/ajpe8481. Epub 2021 May 4. PMID: 34615625; PMCID: PMC8500282.
102. Billingsley HE, **Dixon DL**, Canada JM, Kirkman DL, Rotelli B, Kadariya D, Bohmke N, Markley R, Van Tassell BW,

Celi FS, Abbate A, Carbone S. Time of eating and cardiorespiratory fitness in patients with heart failure with preserved ejection fraction and obesity. *Nutr Metab Cardiovasc Dis*. 2021 Jul 22;31(8):2471-2473. doi: 10.1016/j.numecd.2021.04.018. Epub 2021 Jun 7. PMID: 34112580; PMCID: PMC8277699.

101. **Dixon DL**, Sisson EM, Pamulapati LG, Spence R, Salgado TM. An ounce of prevention is worth a pound of cure: considerations for pharmacists delivering the National Diabetes Prevention Program. *Pharm Pract (Granada)*. 2021 Apr Jun;19(2):2426. doi: 10.18549/PharmPract.2021.2.2426. Epub 2021 May 13. PMID: 34221206; PMCID: PMC8221748.

100. Bonaventura A, Vecchié A, Dagna L, Martinod K, **Dixon DL**, Van Tassell BW, Dentali F, Montecucco F, Massberg S, Levi M, Abbate A. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. *Nat Rev Immunol*. 2021 May;21(5):319-329. doi: 10.1038/s41577-021-00536-9. Epub 2021 Apr 6. PMID: 33824483.

99. Marawan A, Thomas GK, Canada JM, Billingsley HE, **Dixon DL**, Van Tassell BW, Kadariya D, Markley R, Rotelli B, Shah KB, Kang L, Celi FS, Abbate A, Carbone S. Edema Index Predicts Cardiorespiratory Fitness in Patients With Heart Failure With Reduced Ejection Fraction and Type 2 Diabetes Mellitus. *J Am Heart Assoc*. 2021 Apr 20;10(8):e018631. doi: 10.1161/JAHA.120.018631. Epub 2021 Apr 7. PMID: 33825487; PMCID: PMC8174175.

98. Lombardi M, Carbone S, Del Buono MG, Chiabrando JG, Vescovo GM, Camilli M, Montone RA, Vergallo R, Abbate A, Biondi-Zoccai G, **Dixon DL**, Crea F. Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta analysis of randomized controlled trials. *Eur Heart J Cardiovasc Pharmacother*. 2021 Jul 23;7(4):e69-e70. doi: 10.1093/ehjcvp/pvab008. PMID: 33910233; PMCID: PMC8302253.

Press Coverage: [Fish oil supplements linked with heart rhythm disorder](#). European Society of Cardiology Press Office. April 28, 2021.

97. Alagheband Z, Zachariah S, Thomas D, **Dixon DL**. Lipid profile outcome gaps of Arabs and South Asians receiving chronic statin therapy. *Int J Res Pharm Sci*. 2021;11(SPL4):2194-2200. doi: 10.26452/ijrps.v11iSPL4.4442.

96. Salgado TM, Barker MR, Frerichs JD, Musselman KT, **Dixon DL**, Fernandez-Llimos F. Identifying Training Needs and Active Information Opportunities in Primary Care Through the Analysis of Drug Information Requests. *J Pharm Pract*. 2022 Aug;35(4):559-567. doi: 10.1177/0897190021996976. Epub 2021 Mar 5. PMID: 33663257.

95. Fatani N, **Dixon DL**, Van Tassell BW, Fanikos J, Buckley LF. Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. *J Am Coll Cardiol*. 2021 Mar 16;77(10):1290-1299. doi: 10.1016/j.jacc.2021.01.014. PMID: 33706870; PMCID: PMC7959178.

Editorial: Bakris G, Sternlicht H. Time in Therapeutic Range: Redefining "Optimal" Blood Pressure Control. *J Am Coll Cardiol*. 2021 Mar 16;77(10):1300-1301. doi: 10.1016/j.jacc.2021.01.019. PMID: 33706871.

Press Coverage: Cardiology Today. [Time in systolic BP target range predicts major CV event risk](#). R Zusman. March 16, 2021.

Recognition: Listed as one of the Top 100 papers of 2021 by the Editor-in-Chief for *J Am Coll Cardiol*

94. **Dixon DL**, Saseen JJ. Pharmacist-administered long-acting injectable PCSK9 service: A solution to improve patient access and adherence. *J Am Pharm Assoc* (2003). 2021 May-Jun;61(3):e83-e85. doi: 10.1016/j.japh.2020.12.009. Epub 2020 Dec 29. PMID: 33384242.

93. Salgado TM, Reynolds TN, Frankart LM, Holdford DA, Dipiro JT; VCU School of Pharmacy KPIs Redefinition Taskforce [...**Dixon DL**]. A key performance indicators redefinition initiative at a school of pharmacy using a modified Delphi consensus technique. *Pharm Pract (Granada)*. 2020 Oct Dec;18(4):2120. doi: 10.18549/PharmPract.2020.4.2120. Epub 2020 Nov 24. PMID: 33294062; PMCID: PMC7699828.

92. **Dixon DL**. The student loan debt crisis is undermining our profession. *J Am Pharm Assoc* (2003). 2021 Mar

Apr;61(2):127-128. doi: 10.1016/j.japh.2020.11.016. Epub 2020 Dec 16. PMID: 33736840. **[Guest Editorial]**

91. ****Khadage SJ**, Patterson JA, Sargent LJ, Price ET, **Dixon DL**. Sex and Age Differences in Ambulatory Blood Pressure Monitoring Tolerability. *Am J Hypertens*. 2020 Nov 12;hpa182. doi: 10.1093/ajh/hpaa182. Epub ahead of print. PMID: 33180905.

90. **Dixon DL**. Introducing Emerging Concepts in Pharmacotherapeutics. *J Cardiovasc Pharmacol*. 2020 Oct;76(4):372-373. doi: 10.1097/FJC.0000000000000904. PMID: 33027193. **[Invited Editorial]**

89. Salgado TM, Rosenthal MM, Coe AB, Kaefer TN, **Dixon DL**, Farris KB. Primary healthcare policy and vision for community pharmacy and pharmacists in the United States. *Pharm Pract (Granada)*. 2020 Jul-Sep;18(3):2160. doi: 10.18549/PharmPract.2020.3.2160. Epub 2020 Sep 18. PMID: 33029264; PMCID: PMC7523559.

88. J Sargent L, Mackiewicz M, Roman Y, Diallo A, Russell S, Falls K, Zimmerman KM, **Dixon DL**, Prom-Wormley E, Hobgood S, Lageman SK, Zanjani F, Price ET. The Translational Approaches to Personalized Health Collaborative: Pharmacogenomics for African American Older Adults. *Clin Transl Sci*. 2021 Mar;14(2):437-444. doi: 10.1111/cts.12885. Epub 2020 Oct 7. PMID: 33026148; PMCID: PMC7993264.

87. Lombardi M, Chiabrando JG, Vescovo GM, Bressi E, Del Buono MG, Carbone S, Koenig RA, Van Tassell BW, Abbate A, Biondi-Zoccai G, ***Dixon DL**. Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise And Network Meta-analysis. *Curr Atheroscler Rep*. 2020 Jul 16;22(9):45. doi: 10.1007/s11883-020-00865-5. PMID: 32671519.

86. **Dixon DL**, Patterson JA, Gatewood S, Kaefer T, Jadallah J, Curtis M, Hawkey L, Grigsby J, Salgado TM, Holdford DA. Development and feasibility of a community pharmacy-driven 24-hour ambulatory blood pressure monitoring service. *J Am Pharm Assoc* (2003). 2020 Nov-Dec;60(6):e332 e340. doi: 10.1016/j.japh.2020.06.007. Epub 2020 Jul 19. PMID: 32665096.

Press Coverage:

- Pharmacy Times. [Community Pharmacies Implement Innovative 24-hour Ambulatory Blood Pressure Monitoring Service](#). L. Uildriks. December 9, 2020.
- SunTech Medical. [Ambulatory Blood Pressure Monitoring in the Community Pharmacy](#). February 7, 2020.

85. Carbone S, Billingsley HE, Canada JM, Bressi E, Rotelli B, Kadariya D, **Dixon DL**, Markley R, Trankle CR, Cooke R, Rao K, B Shah K, Medina de Chazal H, Chiabrando JG, Vecchié A, Dell M, L Mihalick V, Bogaev R, Hart L, Van Tassell BW, Arena R, Celi FS, Abbate A. The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study. *Diabetes Metab Res Rev*. 2020 Nov;36(8):e3335. doi: 10.1002/dmrr.3335. Epub 2020 Jun 15. PMID: 32415802; PMCID: PMC7685099.

84. Roman YM, **Dixon DL**, Salgado TM, Price ET, Zimmerman KM, Sargent L, Slattum PW. Challenges in pharmacotherapy for older adults: a framework for pharmacogenomics implementation. *Pharmacogenomics*. 2020 Jun;21(9):627-635. doi: 10.2217/pgs-2019-0198. Epub 2020 May 19. PMID: 32425117.

83. **Dixon DL**, Khadage S, Bhagat S, Koenig RA, Salgado TM, Baker WL. Effect of pharmacist interventions on reducing low-density lipoprotein cholesterol (LDL-C) levels: A systematic review and meta-analysis. *J Clin Lipidol*. 2020 May Jun;14(3):282-292.e4. doi: 10.1016/j.jacl.2020.04.004. Epub 2020 Apr 15. PMID: 32418821.

82. **Dixon DL**, Van Tassell BW, Vecchié A, Bonaventura A, Talasaz AH, Kakavand H, D'Ascenzo F, Perciaccante A, Castagno D, Ammirati E, Biondi-Zoccai G, Stevens MP, Abbate A. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). *J Cardiovasc Pharmacol*. 2020 May;75(5):359-367. doi: 10.1097/FJC.0000000000000836. PMID: 32282502; PMCID: PMC7219860. **[Invited Rapid Communication]**

Recognition: Editor's Pick for the May issue of *J Cardiovasc Pharmacol*

81. **Dixon DL**, Carbone S. Screening, identification, and management of prediabetes to reduce cardiovascular risk: A missed opportunity? *Diabetes Metab Res Rev*. 2020 Sep;36(6):e3316. doi: 10.1002/dmrr.3316. Epub 2020 Apr 15. PMID: 32223033.

80. **Dixon DL**, Baker WL. Measuring research impact in the 21st century: are alternative metrics the answer? *Minerva Cardio Angiol.* 2020 Aug;68(4):279-281. doi: 10.23736/S0026-4725.20.05241-X. Epub 2020 Mar 11. PMID: 32163245. **[Invited Editorial]**
79. ****Wagner TD**, Jones MC, Salgado TM, **Dixon DL**. Pharmacist's role in hypertension management: a review of key randomized controlled trials. *J Hum Hypertens.* 2020 Jul;34(7):487-494. doi: 10.1038/s41371-020-0331-7. Epub 2020 Apr 1. PMID: 32238889. **[Invited Review]**
78. Billingsley HE, **Dixon DL**, Gipson G, Abbate A, Carbone S. Time restricted feeding: old tools, new packaging? *Minerva Cardio Angiol.* 2020 Dec;68(6):539-541. doi: 10.23736/S0026-4725.20.052536. Epub 2020 Mar 27. PMID: 32221275. **[Invited Editorial]**
77. **Dixon DL**. Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk. *Am J Med.* 2020 Jul;133(7):802-804. doi: 10.1016/j.amjmed.2020.03.006. Epub 2020 Mar 31. PMID: 32243872. **[Invited Review]**
76. ****Board C**, Kelly MS, Shapiro MD, **Dixon DL**. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy. *J Cardiovasc Pharmacol.* 2020 May;75(5):410-420. doi: 10.1097/FJC.0000000000000809. PMID: 32379108. **[Invited Review]**
75. Wiggins BS, **Dixon DL**, Neyens RR, Page RL 2nd, Gluckman TJ. Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week. *J Am Coll Cardiol.* 2020 Mar 24;75(11):1341-1350. doi: 10.1016/j.jacc.2019.12.068. PMID: 32192661.
74. Abbate A, Trankle CR, Buckley LF, Lipinski MJ, Appleton D, Kadariya D, Canada JM, Carbone S, Roberts CS, Abouzaki N, Melchior R, Christopher S, Turlington J, Mueller G, Garnett J, Thomas C, Markley R, Wohlford GF, Puckett L, Medina Chazal H, Chiabrando JG, Bressi E, Del Buono MG, Schatz A, Vo C, **Dixon DL**, Biondi-Zoccai GG, Kontos MC, Van Tassel BW. Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction. *J Am Heart Assoc.* 2020 Mar 3;9(5):e014941. doi: 10.1161/JAHA.119.014941. Epub 2020 Mar 3. PMID: 32122219; PMCID: PMC7335541.
73. Jia X, Ramsey DJ, Rifai MA, Ahmed ST, Akeroyd JM, **Dixon DL**, Gluckman TJ, Nambi V, Ballantyne CM, Petersen LA, Stone NJ, Virani SS. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). *Am J Cardiol.* 2020 Mar 15;125(6):874-879. doi: 10.1016/j.amjcard.2019.12.030. Epub 2019 Dec 27. PMID:31952841.
72. Lombardi M, Chiabrando JG, Vescovo GM, Bressi E, Del Buono MG, Carbone S, Koenig R, Van Tassel BW, **Dixon DL**, Abbate A, Biondi Zoccai G. Efficacy of different doses of omega-3 fatty acids on cardiovascular outcomes: rationale and design of a network meta-analysis. *Minerva Cardio Angiol.* 2020 Feb;68(1):47-50. doi: 10.23736/S0026-4725.19.05117-X. PMID: 32107906.
71. Del Buono MG, Bonaventura A, Vecchié A, Wohlford GF, **Dixon DL**, Van Tassel BW, Abbate A. Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon? *J Cardiovasc Pharmacol.* 2020 Feb;75(2):105-107. doi: 10.1097/FJC.0000000000000782. PMID: 31815825. **[Invited Editorial]**
70. **Dixon DL**, Wohlford GF 4th, Abbate A. Inflammation and Hypertension: Causal or Not? *Hypertension.* 2020 Feb;75(2):297-298. doi: 10.1161/HYPERTENSIONAHA.119.14195. Epub 2019 Dec 30. PMID: 31884858. **[Invited Editorial]**
69. **Dixon DL**, Baker W. Short-term impact of Altmetric Attention Scores on citation counts in selected major pharmacy journals. *J Am Coll Clin Pharm.* 2020;3(1):10-14. doi: 10.1002/jac5.1141. Epub 2019 June 1.
- Editorial** Thompson DF. Altmetrics: Not ready for PrimeTime? *J Am Coll Clin Pharm.* 2019;3(1):4-5. doi: 10.1002/jac5.1165.

68. **Dixon DL**, Parod ED, Sisson EM, Van Tassell BW, Nadpara P, Dow A. Impact of a pharmacist physician collaborative care model on time-in-therapeutic blood pressure range in patients with hypertension. *J Am Coll Clin Pharm.* 2020;3(2):404-409. doi: 10.1002/jac5.1115. Epub 11 Apr 2019.
67. Gipson GT, Carbone S, Wang J, **Dixon DL**, Jovin IS, Carl DE, Gehr TW, Ghosh S. Impaired Delivery of Cholesterol Effluxed From Macrophages to Hepatocytes by Serum From CKD Patients May Underlie Increased Cardiovascular Disease Risk. *Kidney Int Rep.* 2019 Nov 9;5(2):199-210. doi: 10.1016/j.ekir.2019.11.003. PMID: 32043034; PMCID: PMC7000844.
66. Salgado TM, Patterson JA, Bajaj SK, Lajthia E, Zimmerman KM, Fernandez-Llimos F, **Dixon DL**. Characterization of pharmacy practice research centers across the United States. *Res Social Adm Pharm.* 2020 Feb;16(2):230-237. doi: 10.1016/j.sapharm.2019.05.009. Epub 2019 May 22. PMID: 31155477.
65. Bucheit JD, Pamulapati LG, Carter N, Malloy K, **Dixon DL**, Sisson EM. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. *Diabetes Technol Ther.* 2020 Jan;22(1):10-18. doi: 10.1089/dia.2019.0185. Epub 2019 Oct 1. PMID: 31436480.
64. Wiggins BS, **Dixon D**, Bellone J, Gasbarro N, Marrs JC, Tran R. Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update. *J Pharm Pract.* 2020 Dec;33(6):882-894. doi: 10.1177/0897190019868413. Epub 2019 Aug 11. PMID: 31401932.
63. Lajthia E, Bucheit JD, Nadpara PA, **Dixon DL**, Caldas LM, Murchie M, Sisson EM. Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series. *Pharm Pract (Granada).* 2019 Oct-Dec;17(4):1588. doi: 10.18549/PharmPract.2019.4.1588. Epub 2019 Dec 12. PMID: 31897252; PMCID: PMC6935552.
62. **Dixon DL**, Virani SS. Mortality reduction with PCSK9 inhibition: A case of cautious optimism. *J Clin Lipidol.* 2019 Sep Oct;13(5):712-713. doi: 10.1016/j.jacl.2019.06.012. Epub 2019 Jul 4. PMID: 31371269. **[Invited Editorial]**
61. **Dixon DL**, Salgado TM, Luther JM, Byrd JB. Medicare reimbursement policy for ambulatory blood pressure monitoring: A qualitative analysis of public comments to the Centers for Medicare and Medicaid Services. *J Clin Hypertens (Greenwich).* 2019 Dec;21(12):1803-1809. doi: 10.1111/jch.13719. Epub 2019 Oct 23. PMID: 31642596; PMCID: PMC7018518.
- Editorial:** Ash GI. Revisions of Medicare reimbursement policy for ambulatory blood pressure monitoring and the role of qualitative analysis. *J Clin Hypertens (Greenwich).* 2019 Dec;21(12):1810-1812. doi: 10.1111/jch.13715. Epub 2019 Oct 23. PMID: 31642575.
60. **Dixon DL**, Sharma G, Sandesara PB, Yang E, Braun LT, Mensah GA, Sperling LS, Deedwania PC, Virani SS. Therapeutic Inertia in Cardiovascular Disease Prevention: Time to Move the Bar. *J Am Coll Cardiol.* 2019 Oct 1;74(13):1728-1731. doi: 10.1016/j.jacc.2019.08.014. PMID: 31558257.
59. Robinson JG, Jayanna MB, Brown AS, Aspary K, Orringer C, Gill EA, Goldberg A, Jones LK, Maki K, **Dixon DL**, Saseen JJ, Soffer D. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. *J Clin Lipidol.* 2019 Jul-Aug;13(4):525-537. doi: 10.1016/j.jacl.2019.05.005. Epub 2019 May 16. PMID: 31281070.
58. Carbone S, **Dixon DL**. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. *Cardiovasc Diabetol.* 2019 May 28;18(1):64. doi: 10.1186/s12933-019-0869-2. PMID: 31138195; PMCID: PMC6540565.
57. Carbone S, Billingsley HE, Canada JM, Kadariya D, Medina de Chazal H, Rotelli B, Potere N, Paudel B, Markley R, **Dixon DL**, Trankle CR, Van Tassell BW, Celi FS, Abbate A. Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Patients With Obesity and HFpEF: The UFA-Preserved Pilot Study. *JACC Basic Transl Sci.* 2019 Aug 26;4(4):563-565. doi: 10.1016/j.jacbts.2019.04.001. PMID: 31468011; PMCID: PMC6712039.

56. **Dixon DL**, Reed B. To Tweet or Not to Tweet? A Primer on Social Media for Pharmacists. *J Am Coll Clin Pharm*. 2019;2:554-562. doi: 10.1002/jac5.1120. Epub 2 May 2019. **[Invited Commentary]**

Editorial: Abebe E, Zillich AJ. Please like, follow, subscribe, and share. *J Am Coll Clin Pharm*. 2019;2:452-454.

Press Coverage: Featured on ACCP Journals Podcast. [Episode 18](#). October 14, 2019.

Recognition: [Top 5 most downloaded paper of 2019](#)

55. **Dixon DL**, Pamulapati LG, Bucheit JD, Sisson EM, Smith SR, Kim CJ, Wohlford GF, Pozen J. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. *Curr Atheroscler Rep*. 2019 Mar 16;21(5):16. doi: 10.1007/s11883-019-0778-6. PMID: 30877491. **[Invited Review]**

54. Salgado TM, **Dixon DL**. Practice Forum: A new section led by the Center for Pharmacy Practice Innovation at Virginia Commonwealth University School of Pharmacy. *Pharm Pract (Granada)*. 2019 Jan-Mar;17(1):1495. doi: 10.18549/PharmPract.2019.1.1495. Epub 2019 Mar 18. PMID: 31015882; PMCID: PMC6463415.

53. Bonaventura A, Carbone S, **Dixon DL**, Abbate A, Montecucco F. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists. *J Intern Med*. 2019 Jul;286(1):16-31. doi: 10.1111/joim.12890. Epub 2019 Mar 19. PMID: 30888088.

Recognition: Among the top 10% of most downloaded papers for 2018-2019

52. **Dixon DL**, Johnson SG. Provider Status: What does it mean? *J Am Coll Clin Pharm*. 2019; 2(1):87 doi: 10.1002/jac5.1054. Epub 31 Oct 2018. **[Letter to the Editor]**

51. Noel ZR, Beavers CJ, Dunn SP, Schullo-Feulner AM, Caldas L, **Dixon DL**. Identifying Core Content for Electrocardiogram Instruction in Doctor of Pharmacy Curricula. *Am J Pharm Educ*. 2018 Dec;82(10):7009. doi: 10.5688/ajpe7009. PMID: 30643314; PMCID: PMC6325467.

50. Carbone S, **Dixon DL**, Buckley LF, Abbate A. Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. *Mayo Clin Proc*. 2018 Nov;93(11):1629-1647. doi: 10.1016/j.mayocp.2018.07.018. Erratum in: *Mayo Clin Proc*. 2019 Mar;94(3):554. PMID: 30392544; PMCID: PMC6501786.

49. Longyhore DS, **Dixon DL**, Noel ZR. A Modified Approach to Setting Curriculum Boundaries in Pharmacy School. *Am J Pharm Educ*. 2018 Nov;82(9):7010. doi: 10.5688/ajpe7010. PMID: 30559503; PMCID: PMC6291673.

48. Van Tassel BW, Trankle CR, Canada JM, Carbone S, Buckley L, Kadariya D, Del Buono MG, Billingsley H, Wohlford G, Viscusi M, Oddi-Erdle C, Abouzaki NA, **Dixon D**, Biondi-Zoccai G, Arena R, Abbate A. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. *Circ Heart Fail*. 2018 Aug;11(8):e005036. doi: 10.1161/CIRCHEARTFAILURE.118.005036. PMID: 30354558; PMCID: PMC6545106.

47. Carbone S, **Dixon DL**. Selecting appropriate weight loss pharmacotherapies in older adults to reduce cardiovascular risk. *Expert Opin Pharmacother*. 2018 Sep;19(13):1399-1402. doi: 10.1080/14656566.2018.1511704. Epub 2018 Aug 16. PMID: 30113233. **[Invited Editorial]**

46. Trivedi M, Jee J, Silva S, Blomgren C, Pontinha VM, **Dixon DL**, Van Tassel B, Bortner MJ, Williams C, Gilmer E, Haring AP, Halper J, Johnson BN, Kong Z, Halquist MS, Rocheleau PF, Long TE, Roper T, Wijesinghe DS. Additive manufacturing of pharmaceuticals for precision medicine applications: A review of the promises and perils in implementation. *Additive Manufacturing*. 2018;23:319-328. doi: 10.1016/j.addma.2018.07.004. Epub 2018 Jul 18.

45. Sisson EM, **Dixon DL**, Dow AW. A Trial of Blood-Pressure Reduction in Black Barbershops. *N Engl J Med*. 2018 Jul 12;379(2):200. doi: 10.1056/NEJMc1806026. PMID: 29998726. **[Letter to the Editor]**

44. **Dixon DL**, Salgado TM, Caldas LM, Van Tassell BW, Sisson EM. The 2017 American College of Cardiology/American Heart Association hypertension guideline and opportunities for community pharmacists. *J Am Pharm Assoc (2003)*. 2018 Jul Aug;58(4):382-386. doi: 10.1016/j.japh.2018.04.027. Epub 2018 May 24. PMID: 29804824.
43. **Ayers J**, **Cook J**, Koenig RA, Sisson EM, **Dixon DL**. Recent Developments in the Role of Coenzyme Q10 for Coronary Heart Disease: a Systematic Review. *Curr Atheroscler Rep*. 2018 May 16;20(6):29. doi: 10.1007/s11883-018-0730-1. PMID: 29766349. **[Invited Review]**
42. Carbone S, Canada JM, Billingsley HE, Kadariya D, **Dixon DL**, Trankle CR, Buckley LF, Markley R, Vo C, Medina de Chazal H, Christopher S, Buzzetti R, Van Tassell BW, Abbate A. Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. *Diabetes Obes Metab*. 2018 Aug;20(8):2014-2018. doi: 10.1111/dom.13309. Epub 2018 Apr 23. PMID: 29603546; PMCID: PMC6043379.
41. Zimmerman KM, Salgado TM, Goode JR, Sisson EM, **Dixon DL**. A Prescription for Prescribing: Ensuring Continued Pharmacist Preparedness. *Ann Pharmacother*. 2018 Jul;52(7):697-699. doi: 10.1177/1060028018763519. Epub 2018 Mar 7. PMID: 29514464. **[Invited Commentary]**
40. Buckley LF, **Dixon DL**, Wohlford GF 4th, Wijesinghe DS, Baker WL, Van Tassell BW. Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants. *Diabetes Obes Metab*. 2018 Jun;20(6):1499-1502. doi: 10.1111/dom.13248. Epub 2018 Mar 2. PMID: 29424469.
- Editorial** Laffin LJ, Bakris GL. Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes. *Diabetes Obes Metab*. 2018 Jun;20(6):1335-1336. doi: 10.1111/dom.13249. Epub 2018 Feb 28. PMID: 29424470; PMCID: PMC5948152.
39. Sisson EM, Pamulapati L, Bucheit JD, Kelly MS, **Dixon DL**. Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. *Pharmacotherapy*. 2018 Feb;38(2):164-171. doi: 10.1002/phar.2074. Epub 2018 Jan 10. PMID: 29266309. **[Invited Commentary]**
- Press Coverage**: Featured on *Pharmacotherapy* Podcast. [Episode 21: Evolving Role of Non-Statin Therapy](#). S. Haines. March 14, 2018.
38. Carbone S, **Dixon DL**, Abbate A. Treatment of Hypertension to Prevent and Treat Heart Failure in Diabetic Patients Should Include Sodium Glucose Co-Transporter 2 Inhibitors. *JACC Heart Fail*. 2018 Jan;6(1):85. doi: 10.1016/j.jchf.2017.07.008. PMID: 29284585. **[Letter to the Editor]**
37. Bucheit JD, Helsing H, Nadpara P, Virani SS, **Dixon DL**. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. *J Clin Lipidol*. 2018 Mar-Apr;12(2):367-374.e3. doi: 10.1016/j.jacl.2017.11.010. Epub 2017 Dec 6. PMID: 29277495.
36. **Dixon DL**, Sisson EM, Parod ED, Van Tassell BW, Nadpara PA, Carl D, W Dow A. Pharmacist physician collaborative care model and time to goal blood pressure in the uninsured population. *J Clin Hypertens (Greenwich)*. 2018 Jan;20(1):88-95. doi: 10.1111/jch.13150. Epub 2017 Dec 13. PMID: 29237095.
- Editorial** Carter BL. Collaborative care model for hypertension. *J Clin Hypertens (Greenwich)*. 2018 Jan;20(1):96-97. doi: 10.1111/jch.13142. Epub 2017 Dec 13. PMID: 29237101.
35. Littauer SL, **Dixon DL**, Mishra VK, Sisson EM, Salgado TM. Pharmacists providing care in the outpatient setting through telemedicine models: a narrative review. *Pharm Pract (Granada)*. 2017 Oct Dec;15(4):1134. doi: 10.18549/PharmPract.2017.04.1134. Epub 2017 Dec 19. PMID: 29317927; PMCID: PMC5742004.
34. Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Oddi Erdle C, Abouzaki NA, **Dixon D**, Kadariya D, Christopher S, Schatz A, Regan J, Viscusi M, Del Buono M, Melchior R, Mankad P, Lu J, Sculthorpe R, Biondi-Zoccai G,

Lesnefsky E, Arena R, Abbate A. Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). *Circ Heart Fail*. 2017 Nov;10(11):e004373. doi: 10.1161/CIRCHEARTFAILURE.117.004373. PMID: 29141858; PMCID: PMC5699505.

33. Buckley LF, **Dixon DL**, Wohlford GF 4th, Wijesinghe DS, Baker WL, Van Tassell BW. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. *Diabetes Care*. 2017 Dec;40(12):1733-1738. doi: 10.2337/dc17-1366. Epub 2017 Sep 25. PMID: 28947569.

Press Coverage

- Endocrine Today. [Intensive BP control may reduce CV events in high-risk patients with type 2 diabetes](#). R. Schaffer. September 26, 2017
- iForumRx. [SPRINTing towards lower BP goals: A re-analysis of the ACCORD-BP trial](#). K. Cowart, K. Sando. February 2, 2018.

32. Hylton Gravatt LA, Flurie RW, Lajthia E, **Dixon DL**. Clinical Guidance for Managing Statin and Antimicrobial Drug Drug Interactions. *Curr Atheroscler Rep*. 2017 Oct 9;19(11):46. doi: 10.1007/s11883-017-0682-x. PMID: 28990114. **[Invited Review]**

31. Zimmerman KM, Salgado TM, **Dixon DL**. Medication Reconciliation vs Medication Review. *JAMA*. 2017 Sep 12;318(10):965-966. doi: 10.1001/jama.2017.10552. PMID: 28898372. **[Letter to the Editor]**

30. **Dixon DL**, Salgado TM, Abbate A. Pharmacists as Integral Members of the Cardiovascular Team. *JAMA Cardiol*. 2017 Nov 1;2(11):1279-1280. doi: 10.1001/jamacardio.2017.2795. PMID: 28832861. **[Letter to the Editor]**

29. ****Kelly MS**, Beavers C, Bucheit JD, Sisson EM, **Dixon DL**. Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150-499 mg/dL). *J Clin Lipidol*. 2017 Jul-Aug;11(4):872-879. Doi: 10.1016/j.jacl.2017.05.014. Epub 2017 Jun 6. PMID: 28669686.

28. **Dixon DL**, Buckley LF, Trankle CR, Kadariya D, Abbate A. Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. *Drug Des Devel Ther*. 2017 Jul 11;11:2121-2129. doi: 10.2147/DDDT.S114091. PMID: 28744103; PMCID: PMC5513834. **[Invited Review]**

27. Carbone S, Canada JM, Buckley LF, Trankle CR, Billingsley HE, **Dixon DL**, Mauro AG, Dessie S, Kadariya D, Mezzaroma E, Buzzetti R, Arena R, Van Tassell BW, Toldo S, Abbate A. Dietary Fat, Sugar Consumption, and Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction. *JACC Basic Transl Sci*. 2017 Oct 30;2(5):513-525. doi: 10.1016/j.jacbts.2017.06.009. PMID: 30062167; PMCID: PMC6058958.

26. Baker WL, Buckley LF, Kelly MS, Bucheit JD, Parod ED, Brown R, Carbone S, Abbate A, **Dixon DL**. Effects of Sodium Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. *J Am Heart Assoc*. 2017 May 18;6(5):e005686. doi: 10.1161/JAHA.117.005686. PMID: 28522675; PMCID: PMC5524106.

25. Trankle C, Canada JM, Buckley L, Carbone S, **Dixon D**, Arena R, Van Tassell B, Abbate A. Impaired myocardial relaxation with exercise determines peak aerobic exercise capacity in heart failure with preserved ejection fraction. *ESC Heart Fail*. 2017 Aug;4(3):351-355. doi: 10.1002/ehf2.12147. Epub 2017 May 6. PMID: 28772034; PMCID: PMC5542717.

24. Van Tassell BW, Buckley LF, Carbone S, Trankle CR, Canada JM, **Dixon DL**, Abouzaki N, Oddi Erdle C, Biondi-Zoccai G, Arena R, Abbate A. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (DHART2). *Clin Cardiol*. 2017 Sep;40(9):626-632. doi: 10.1002/clc.22719. Epub 2017 May 5. PMID: 28475816; PMCID: PMC5744484.

23. Carbone S, Canada JM, Buckley LF, Trankle CR, **Dixon DL**, Buzzetti R, Arena R, Van Tassell BW, Abbate A. Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. *J Am Coll Cardiol*. 2016 Dec 6;68(22):2487-2488. doi: 10.1016/j.jacc.2016.08.072. PMID: 27908355; PMCID: PMC5748881.

22. Van Tassell BW, Abouzaki NA, Oddi Erdle C, Carbone S, Trankle CR, Melchior RD, Turlington JS, Thurber CJ, Christopher S, **Dixon DL**, Fronk DT, Thomas CS, Rose SW, Buckley LF, Dinarello CA, Biondi-Zoccai G, Abbate A. Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study. *J Cardiovasc Pharmacol*. 2016 Jun;67(6):544-51. doi: 10.1097/FJC.0000000000000378. PMID: 26906034; PMCID: PMC5749643.
21. **Dixon DL**, Carbone S, Abbate A. Letter by Dixon et al Regarding Article, "Watching Television and Risk of Mortality From Pulmonary Embolism Among Japanese Men and Women: The JACC Study (Japan Collaborative Cohort)". *Circulation*. 2016 Nov 22;134(21):e499-e500. doi: 10.1161/CIRCULATIONAHA.116.024740. PMID: 27881514. **[Letter to the Editor]**
20. **Dixon DL**, Trankle C, Buckley L, Parod E, Carbone S, Van Tassell BW, Abbate A. A review of PCSK9 inhibition and its effects beyond LDL receptors. *J Clin Lipidol*. 2016 Sep-Oct;10(5):1073-80. doi: 10.1016/j.jacl.2016.07.004. Epub 2016 Jul 20. PMID: 27678423.
19. Buckley L, Wijesinghe D, **Dixon D**, Trankle C, Carbone S, Canada J, Van Tassell B. The State of Women's Health in 2016 and Future Perspectives. *Ann Public Health Res*. 2016;3(2):1041.
18. Sisson EM, **Dixon DL**, Kildow DC, Van Tassell BW, Carl DE, Varghese D, Electricwala B, Carroll NV. Effectiveness of a Pharmacist-Physician Team-Based Collaboration to Improve Long-Term Blood Pressure Control at an Inner-City Safety-Net Clinic. *Pharmacotherapy*. 2016 Mar;36(3):342-7. doi: 10.1002/phar.1710. Epub 2016 Feb 24. PMID: 26917116.
17. **Dixon DL**, Dunn SP, Kelly MS, McLarky TR, Brown RE. Effectiveness of Pharmacist-Led Amiodarone Monitoring Services on Improving Adherence to Amiodarone Monitoring Recommendations: A Systematic Review. *Pharmacotherapy*. 2016 Feb;36(2):230-6. doi: 10.1002/phar.1697. Epub 2016 Feb 5. PMID: 26846446.
16. Canada JM, Fronk DT, Cei LF, Carbone S, Erdle CO, Abouzaki NA, Melchior RD, Thomas CS, Christopher S, Turlington JS, Trankle CR, Thurber CJ, Evans RK, **Dixon DL**, Van Tassell BW, Arena R, Abbate A. Usefulness of C-Reactive Protein Plasma Levels to Predict Exercise Intolerance in Patients with Chronic Systolic Heart Failure. *Am J Cardiol*. 2016 Jan 1;117(1):116-20. doi: 10.1016/j.amjcard.2015.10.020. Epub 2015 Oct 19. PMID: 26546248.
15. Sperling LS, Mechanick JI, Neeland IJ, Herrick CJ, Després JP, Ndumele CE, Vijayaraghavan K, Handelsman Y, Puckrein GA, Araneta MR, Blum QK, Collins KK, Cook S, Dhurandhar NV, **Dixon DL**, Egan BM, Ferdinand DP, Herman LM, Hessen SE, Jacobson TA, Pate RR, Ratner RE, Brinton EA, Forker AD, Ritzenhaler LL, Grundy SM. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. *J Am Coll Cardiol*. 2015 Sep 1;66(9):1050-67. doi: 10.1016/j.jacc.2015.06.1328. PMID: 26314534.
14. American College of Clinical Pharmacy, McBane SE, Dopp AL, Abe A, Benavides S, Chester EA, **Dixon DL**, Dunn M, Johnson MD, Nigro SJ, Rothrock-Christian T, Schwartz AH, Thrasher K, Walker S. Collaborative drug therapy management and comprehensive medication management-2015. *Pharmacotherapy*. 2015 Apr;35(4):e39-50. doi: 10.1002/phar.1563. PMID: 25884536.
13. Ogbonna KC, **Dixon DL**. Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism. *J Blood Med*. 2015 Jun 11;6:177-84. doi: 10.2147/JBM.S54033. PMID: 26185477; PMCID: PMC4501287.
12. Abbate A, Van Tassell BW, Canada JM, **Dixon DL**, Arena RA, Biondi-Zoccai G. Pharmacologic and surgical interventions to improve functional capacity in heart failure. *Heart Fail Clin*. 2015 Jan;11(1):117-24. doi: 10.1016/j.hfc.2014.08.005. Epub 2014 Oct 3. PMID: 25432480.
11. Carbone S, Buckley L, Trankle C, Canada J, **Dixon D**, Van Tassell B, Buzzetti R, Abbate A. Obesity and Heart Failure: Can Nutrition Status Explain the Paradoxical Relationship? *EC Cardiology*. 2015;2(2):94-98.
10. **Dixon DL**, Donohoe KL, Ogbonna KC, Barden SM. Current drug treatment of hyperlipidemia in older adults. *Drugs Aging*. 2015 Feb;32(2):127-38. doi: 10.1007/s40266-015-0240-6. PMID: 25637391. **[Invited Review]**
9. **Dixon DL**, Abbate A. Potassium levels in acute myocardial infarction: definitely worth paying attention to. *Eur Heart J*

Cardiovasc Pharmacother. 2015 Oct;1(4):252-3. doi: 10.1093/ehjcvp/pvv029. Epub 2015 Jun 18. PMID: 27532448. **[Invited Editorial]**

8. Bishop S, Stewart K, **Dixon D**, Sicat B, Wolver S. Interprofessional education team-based learning series: obesity module. *MedEdPORTAL*. 2015;11:10125. doi: 10.15766/mep_2374-8265.10125.

7. ****Crist LW, Dixon DL**. Considerations for dofetilide use in the elderly. *Consult Pharm*. 2014 Apr;29(4):270-4. doi: 10.4140/TCP.n.2014.270. PMID: 24704896.

6. **Dixon DL**, Sisson EM, Butler M, Higbea A, Muoio B, Turner B. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia. *J Cardiovasc Nurs*. 2014 Sep-Oct;29(5):E7-E12. doi: 10.1097/JCN.000000000000104. PMID: 24231894.

5. **Dixon D**, Lyles A, Sicat B, Lee B, Rybarczyk B, Lord B. Interprofessional team-based learning module: anticoagulation. *MedEdPORTAL*. 2013;9:9334. doi: 10.15766/mep_2374-8265.9334.

4. Yoder VG, **Dixon DL**, Barnette DJ, Beardsley JR. Short-term outcomes of an employer-sponsored diabetes management program at an ambulatory care pharmacy clinic. *Am J Health Syst Pharm*. 2012 Jan 1;69(1):69-73. doi: 10.2146/ajhp110041. PMID: 22180556.

Press Coverage: ASHP Health Policy Alerts. Diabetes Program at Pharmacist-led Clinic Improves Patients' Outcomes, Study Shows. January 11, 2012.

3. ****Gerrald KR, Dixon DL**, Barnette DJ, Williams VG. Evaluation of a pharmacist-managed lipid clinic that uses point-of care lipid testing. *J Clin Lipidol*. 2010 Mar-Apr;4(2):120-5. doi: 10.1016/j.jacl.2010.02.001. Epub 2010 Feb 6. PMID: 21122639.

2. **Dixon DL**, Williams VG. Interaction between gemfibrozil and warfarin: case report and review of the literature. *Pharmacotherapy*. 2009 Jun;29(6):744-8. doi: 10.1592/phco.29.6.744. PMID: 19476425.

1. **Dixon D**, Peek B, Reeve R. Safety of enoxaparin bridge therapy in patients with mechanical heart valves. *Ann Pharmacother*. 2008 Jan;42(1):143-4. doi: 10.1345/aph.1K412. Epub 2007 Nov 27. PMID: 18042810.

PEER-REVIEWED BOOK CHAPTERS

12. **Dixon DL**, Riche DM, Kelly MS (2023). Dyslipidemia (Chapter 32). In: DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey LM. eds. *DiPiro's Pharmacotherapy A Pathophysiologic Approach*, 12e. New York, NY: McGraw Hill.

11. **Dixon DL**, Riche DM (2020). Dyslipidemia (Chapter 31). In: DiPiro JT, Yee GC, Posey L, Haines ST, Nolin TD, Ellingrod V. eds. *Pharmacotherapy: A Pathophysiologic Approach*, 11e. New York, NY: McGraw-Hill.

10. Bucheit J, **Dixon DL** (2020). Pharmacotherapy: Dyslipidemia and Hypertension in Persons with Diabetes (Chapter 20). In: Cornell S, ed. *The Art and Science of Diabetes Self-Management Education, Desk Reference*, 5th edition. Chicago: Association of Diabetes Care & Education Specialists.

9. **Dixon DL**. (2018). Dyslipidemia. In: Baker WL, Beavers C, Bolesta S, et al., eds. *Updates in Therapeutics®: Cardiology Pharmacy Preparatory Review Course*. Lenexa: American College of Clinical Pharmacy.

8. **Dixon DL**, Sisson EM (2018). Primary Prevention of Cardiovascular Disease (Cardiologic Care 1). In: Dong BJ, Elliot DP, eds. *Ambulatory Care Self-Assessment Program Book 1: Cardiologic Care*. Lenexa: American College of Clinical Pharmacy.

7. **Dixon DL** (2017). Best Practice for Switching Stable Warfarin Patients (Chapter 15). In: Kiser K, ed. *Oral Anticoagulation Therapy: Cases and Clinical Correlation*. Cham: Springer International Publishing. DOI 10.1007/978-3-319-54643-8_1

6. **Dixon DL** (2017). Significance of P-glycoprotein (P-gp) Drug-Drug Interactions (Chapter 29). In: Kiser K, ed. *Oral*

Anticoagulation Therapy: Cases and Clinical Correlation. Cham: Springer International Publishing. DOI 10.1007/978-3-319-54643-8_1

5. **Dixon DL**, Bucheit J (2017). Pharmacotherapy: Dyslipidemia and Hypertension (Chapter 19). In: Cornell S, ed. The Art and Science of Diabetes Self-Management Education, Desk Reference, 4th edition. Chicago: Association of Diabetes Care & Education Specialists.
4. **Dixon DL**, Parod E (2013). New FDA recommendations for the use of metformin in patients with mild to moderate renal impairment. Textbook Update. Access Pharmacy Website. <http://www.AccessPharmacy.com>. New York: McGraw-Hill.
3. **Dixon DL** (2015). Taking Medications (Module 4). In: Miller D, ed. Diabetes Education Curriculum: A Guide to Successful Self-Management, 2nd edition. Chicago: Association of Diabetes Care & Education Specialists.
2. **Dixon DL**, Sisson EM (2014). Pharmacotherapy: Dyslipidemia and Hypertension (Chapter 18). In: Mensing C, ed. The Art and Science of Diabetes Self-Management Education, Desk Reference, 3rd edition. Chicago: Association of Diabetes Care & Education Specialists.
1. Sisson EM, **Dixon DL** (2014). Pharmacotherapy for Glucose Management (Chapter 17). In: Mensing C, ed. The Art and Science of Diabetes Self-Management Education, Desk Reference, 3rd edition. Chicago: Association of Diabetes Care & Education Specialists.

PEER-REVIEWED ABSTRACTS AND POSTER PRESENTATIONS (mentee)**

International

5. ****Wagner TD**, Barker MR, Ngo PQ, Ko EE, Martin BA, Squadritto MM, Frerichs JD, Musselman KT, Shin Y, **Dixon DL**, Jones RM, Salgado TM. Contribution of clinical pharmacy services to the achievement of diabetes- and hypertension-related quality measures among Medicare patients. International Society of Pharmacoeconomics and Outcomes Research Annual International Conference. Vienna, Austria; 2022. *Value Health*. 2022;25(Suppl I,SI 12):S289.
4. ****Wagner TD**, **Dixon DL**, Salgado TM. The comparison of SGLT2 inhibitors and DPP-4 inhibitors on health care expenditure and utilization in patients with type 2 diabetes mellitus. International Society of Pharmacoeconomics and Outcomes Research Annual International Conference. Orlando, Florida; 2020. *Value Health* 2020;23(Suppl I,SI 17):PDB48.
3. Derington CG, King JB, Herrick JS, **Dixon DL**, Cohen JB, Shimbo D, Kronish IM, Saseen JJ, Munter P, Moran AE, Bress AP. Factors associated with antihypertensive monotherapy among US adults with treated and uncontrolled blood pressure, NHANES 2013-2018. Joint Meeting of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH) (virtual); Glasgow, UK; April 2021. *J Hyperten*. April 2021;39:e241 doi: 10.1097/01.hjh.0000747184.27176.5a.
2. Van Tassell B, Trankle CR, Kadariya D, Canada JM, Carbone S, Buckley LF, Wohlford GF, **Dixon DL**, Christopher S, Vo C, Mankad P, Dell M, Shah K, Kontos MC, Abbate A. Predictive role of C reactive protein levels in patients with ST-segment elevation acute myocardial infarction for heart failure related events. European Society of Cardiology Congress; Paris, France; September 3, 2019. *Eur J Heart Fail*. 2019;40(Suppl. S1): ehz746.0097.
1. Van Tassell B, Canada J, Carbone S, Trankle C, Buckley LF, Oddi Erdle C, Abouzaki N, **Dixon DL**, Kadariya D, Christopher S, Billingsley H, Regan J, Bhatnagar A, Lesnefsky E, Abbate A. Interleukin-1 blockade in recently decompensated systolic heart failure: the recently decompensated heart failure anakinra response trial (REDHART). 4th World Congress on Acute Heart Failure; Paris, France; May 2017. *Eur J Heart Fail*. 2017;19(Suppl. S1):368. Encore presentation: American College of Clinical Pharmacy Annual Meeting; Orlando, FL; October 2017.

National

63. ****Tran C**, ****Alhomoud I**, Taylor K, Kaefer T, Sabo R, **Dixon DL**. A Comparison of Community Pharmacy Measured

Blood Pressure to 24-hour Ambulatory Blood Pressure Monitoring: Preliminary Findings. American College of Clinical Pharmacy Annual Meeting; November 2023.

62. **Dixon DL**, Robinson A, Salgado T, Carbone S, Wagner T, Hyder H, Kirschner B, Musselman K, Sabo R. Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology and Primary Care Visits in a Community Health System. American Heart Association Scientific Sessions; November 2023. *Circulation*. 2023;148:A12427

61. Lee T, Grandhi GR, Alebna P, Asgharpour A, **Dixon DL**, Salloum FN, Sanyal AJ, Siddiqui M, Mehta A. Discordant Association of Nonalcoholic Fatty Liver Disease With Lipoprotein(a) and Markers of Atherogenic Dyslipidemia. American Heart Association Scientific Sessions; November 2023. *Circulation*. 2023;148:A12321

60. Alebna PL, Grandhi G, Shetty N, Minhas AMK, Chew N, **Dixon DL**, Blaha MJ, Arora P, Siddiqui M, Sanyal A, Mehta A. Association of Cardiovascular Health With Nonalcoholic Fatty Liver Disease in American Adults. American Heart Association Scientific Sessions; November 2023. *Circulation*. 2023;148:A15983

59. Salgado TM, Bradford NM, Zimmerman KM, Musselman KT, Buffington TM, Hyder HS, Seaton TL, **Dixon DL**, Jones RM. Application of the consolidation framework for implementation research to explore factors affecting uptake of SGLT-2 inhibitors and GLP-1 receptor agonists in clinical practice. 15th Annual Conference on the Science of Dissemination and Implementation; December 2022.

58. Zbyrak V, Salgado TM, **Dixon DL**, Radwan R, Sisson EM, Pamulapati LG. Factors affecting job satisfaction among board-certified pharmacists in Virginia. American College of Clinical Pharmacy Global Conference in Clinical Pharmacy; October 2022.

Recognition: Finalist for Best Poster Award

57. Salgado TM, Campbell C, Karim-Nejad L, Sisson EM, **Dixon DL**. Implementation of a diabetes prevention program: Participant feedback on ways to increase recruitment and adaptations to improve retention. 14th Annual Conference on the Science of Dissemination and Implementation in Health (virtual); December 2021.

56. ****Jay JS**, Ijioma SC, Holdford DA, **Dixon DL**, Sisson EM, Patterson JA. The Cost-Benefit of Pharmacist-Physician Collaborative Care Model vs. Usual Care on Time-in-Therapeutic Blood Pressure Range in Patients with Hypertension: From the Payer Perspective. Academy of Managed Care Pharmacy Nexus; October 2021.

Recognition: Best Resident/Fellow Poster Award

55. ****Buckley L**, Baker WL, Van Tassell BW, Cohen J, Alkhezi O, Bress AP, **Dixon DL**. Association Of Systolic Blood Pressure Time-in-target Range With Adverse Kidney And Cardiovascular Outcomes In Adults With And Without Diabetes. American Heart Association Hypertension Scientific Sessions; September 2021. *Hypertension*. 2021;78:A20. https://doi.org/10.1161/hyp.78.suppl_1.20.

Recognition: Selected for Early Career Stage Award for Patient-Oriented or Clinical Research in Hypertension

54. Billingsley HE, **Dixon DL**, Canada JM, Rotelli B, Kadariya D, Markley R, Van Tassell B, Celi FS, Abbate A, Carbone S. Time of Eating and Cardiorespiratory Fitness in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. American Society of Nutrition Annual Meeting (virtual); June 2021. **Recognition: Abstract of Distinction**

53. ****Spence R**, Sisson EM, **Dixon DL**. Survey of CDC-recognized community pharmacies providing the National Diabetes Prevention Program. American College of Clinical Pharmacy Virtual Poster Symposium; May 2021.

Recognition: Awarded Best Poster by Ambulatory Care PRN

52. **Dixon DL**, Baker W, Buckley L, Salgado TM, Van Tassell B, Carter B. Cluster randomized Trial of a Physician/Pharmacist

Collaborative Model to Improve Blood Pressure Control: Post-Hoc Analysis of Time in Therapeutic Range for Systolic Blood Pressure. American College of Cardiology Scientific Sessions (virtual); May 2021. *J Am Coll Cardiol.* 2021 May, 77 (18_Supplement_1) 1477.

Recognition: Selected for Oral Moderated Poster Session

51. Radwan RM, **Dixon DL**, Salgado TM. Predictors of Obtaining Cholesterol Screening in the United States: Data from the 2014 Medical Expenditure Panel Survey. American Pharmacists Association Annual Meeting (virtual); March 2021.

50. Wagner TD, Barker MR, Squadrito MM, Frerichs JD, Martin BA, Musselman KT, Shin Y, **Dixon DL**, Jones RM, Salgado TM. Impact of clinical pharmacy services on the achievement of vaccine-related quality measures in primary care. American Pharmacists Association Annual Meeting (virtual); March 2021.

49. Billingsley HE, **Dixon DL**, Canada JM, Rotelli B, Dell M, Vecchie A, Kadariya D, Markley R, Trankle CR, Medina de Chazal H, Chiabrando JG, Dickson V, Bressi E, Van Tassell BW, Abbate A, Carbone S. Higher Skeletal Muscle Mass Index is Associated with Better Reported Quality of Life and Lower Fatigue in Patients with Heart Failure with Reduced Ejection Fraction and Type 2 Diabetes Mellitus. ASPEN Nutrition Science & Practice Conference (virtual). March 2021.

48. Billingsley HE, **Dixon DL**, Canada JM, Rotelli B, Dell M, Vecchie A, Kadariya D, Markley R, Trankle CR, Medina De Chazal H, Chiabrando GJ, Dickson V, Bressi E, Van Tassell BW, Abbate A, Carbone S. Skeletal Muscle Mass Index by Bioelectrical Impedance Analysis is Strongly Associated with Dual Energy X-Ray Absorptiometry in Patients with Heart Failure with Reduced Ejection Fraction and Type 2 Diabetes Mellitus. ASPEN Nutrition Science & Practice Conference (virtual). March 2021.

Recognition: Selected for Oral Presentation

47. **Dixon DL**, Billingsley HE, Canada JM, Trankle CR, Cooke R, Hart L, Van Tassell B, Abbate A, Carbone S. Effect of Canagliflozin compared to Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study. National Lipid Association Scientific Sessions (virtual). December 10, 2020.

46. Radwan RM, Patterson JA, **Dixon DL**, Salgado TM. Predictors Of Pharmacists' Job Satisfaction: Analysis Of The 2018 Virginia Pharmacist Workforce Survey. American College of Clinical Pharmacy Annual Meeting (virtual). October 2020.

45. Wagner T, Barker MR, Squadrito MM, Frerichs JD, Martin BA, Musselman KT, Shin Y, **Dixon DL**, Jones RM, Salgado TM. Impact of clinical pharmacy services on the achievement of diabetes- and hypertension-related quality measures. American College of Clinical Pharmacy Annual Meeting (virtual). October 2020.

44. Marawan A, Thomas GK, Canada JM, Billingsley H, **Dixon DL**, Van Tassell B, Kadariya D, Markley R, Rotelli B, Shah KB, Celi F, Abbate A, Carbone S. Edema Index Predicts Cardiorespiratory Fitness in Patients with Heart Failure with Reduced Ejection Fraction and Type 2 Diabetes Mellitus. Heart Failure Society of America Annual Meeting (virtual); October 2020. *J Card Fail.* 2020;26(10):S48-S49.

43. Marawan A, Thomas G, Billingsley H, Kadariya D, **Dixon D**, Markley R, Trankle C, Wohlford G, Chiabrando J, Vecchié A, Van Tassell B, Arena R, Abbate A, Carbone S. Bioelectrical Impedance Analysis Identifies Patients With Worse Cardiorespiratory Fitness In Heart Failure With Reduced Ejection Fraction And Type 2 Diabetes Mellitus. Heart Failure Society of America Annual Meeting (virtual); October 2020; *J Card Fail.* 2020;26(10):S48-49.

42. ****K**haddage S, Patterson J, **Dixon DL**. Sex and Age Differences in Ambulatory Blood Pressure Monitoring Tolerability. American Heart Association Hypertension Scientific Sessions; Virtual Meeting; September 10, 2020. *Hypertension.* 2020;76(Suppl_1):AP166. https://doi.org/10.1161/hyp.76.suppl_1.P166.

41. **Dixon DL**, Simmons G, Rodriguez L, Abbate A. An interdisciplinary approach to managing severe hyperlipidemia in a patient with graft versus host disease of the liver. American College of Cardiology Annual Scientific Session; Chicago, IL; March 2020 (virtual). *J Am Coll Cardiol.* 2020;74(11, Suppl 1): DOI: 10.1016/S0735-1097(20)32925-9.

40. **Dixon DL**, Patterson J, Gatewood S, Kaefer T, Jadallah J, Curtis M, Hawkey L, Grigsby J, Salgado TM, Holdford D. Implementation and Evaluation of a 24-Hour Ambulatory Blood Pressure Monitoring Service in Community Pharmacy. American Pharmacists Association Annual Meeting (virtual); Washington, DC; March 2020.
39. Jia X, Ramsey DJ, al Rifai M, Ahmed ST, Akeroyd JM, **Dixon DL**, Gluckman T, Nambi V, Ballantyne CM, Petersen LA, Stone NJ, Virani SS. Lipid Monitoring and Treatment Intensification of Cholesterol Lowering Therapies - Insight from the Veterans Affairs Healthcare System. American Heart Association Scientific Sessions; Philadelphia, PA; November 16, 2019.
38. **Bhagat S**, **Khaddage S**, Baker WL, Koenig RA, Salgado TM, Kelly M, **Dixon DL**. Impact of Pharmacist Interventions on Reducing Low-Density Lipoprotein Cholesterol (LDL-C) Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. American College of Clinical Pharmacy Annual Meeting; New York City, NY; October 26, 2019.
37. Wohlford GF, Ho A, Dell M, Vecchie A, Buckley LF, **Dixon DL**, Van Tassell BW. Predicting hospitalizations for heart failure using measurements of atmosphere and atmosphere quality. American College of Clinical Pharmacy Annual Meeting; New York City, NY; October 26, 2019.
36. Ho A, Wohlford GF, Vecchie A, Dell M, **Dixon DL**, Van Tassell BW. The relationship of air pollutants and heart failure hospitalizations in a medium sized metropolitan city in Virginia. American College of Clinical Pharmacy Annual Meeting; New York City, NY; October 26, 2019.
35. **Hess D**, **Seto S**, Nadpara, Sisson EM, **Dixon DL**. Characterization of Familial Hypercholesterolemia Management at an Academic Medical Center. National Lipid Association Scientific Sessions; Miami, FL; May 2019. *J Clin Lipidol.* 2019;13(3):e39 e40.
34. Billingsley H, Carbone S, Canada J, Buckley L, **Dixon D**, Kadariya D, Wohlford G, Trankle C, Van Tassell B, Abbate A. Omega-3 Red Blood Cell Count is Associated with Fat Mass Index and Leptin in Subjects with Obesity and Heart Failure with Preserved Ejection Fraction. American Society of Nutrition Annual Meeting; Baltimore, MD; June 2019. *Curr Dev Nutr.* 2019 Jun 13;3(Suppl 1). pii: nzz041.P21-001-19.
33. Wohlford GF, Contaifer D, Buckley LF, **Dixon DL**, Price ET, Canada JM, Abbate A, Wijesinghe D, Van Tassell BW. Pathophenotype Development for Patients with Recently Decompensated Heart Failure. American College of Cardiology Scientific Sessions; New Orleans, LA; March 2019. *J Am Coll Cardiol.* 2019;73(9, Suppl 1):979.
32. Fatani N, **Dixon DL**, Van Tassell BW, Buckley LF, Fanikos J. Longer Time in Therapeutic Blood Pressure Range Protects Against Major Adverse Cardiovascular Events and All-Cause Mortality in Patients with Hypertension: A Post-hoc Analysis of SPRINT. American Heart Association Scientific Sessions; Orlando, FL; November 2018. *Circulation.* 2018;138 (Suppl 1):A14190.

Recognition: Selected for Oral Presentation

31. **Dixon DL**, Parod ED, Sisson EM, Van Tassell BW, Nadpara P, Dow A. Pharmacist Physician Collaborative Care Model vs. Standard Care: Assessing Time in Therapeutic Range in Patients with Hypertension. American College of Clinical Pharmacy Global Conference; Seattle, WA; October 22, 2018. *J Am Coll Clin Pharm.* 2018;1:135.
30. Wohlford GF, Buckley LF, **Dixon DL**, Baker WL, Van Tassell BW. Antidepressant use in TOPCAT America's. Heart Failure Society of America Annual Meeting; Nashville, TN; September 15, 2018. *J Card Fail.* 2018;24(8S):S60-S61.
29. Caldas LM, Basco H, Barthlow M, Funn D, Salgado TM, **Dixon DL**, Sisson EM. Student Pharmacist-Led Implementation of the National Diabetes Prevention Program in an Urban-Free Clinic. Association of Diabetes Care & Education Specialists Annual meeting; Baltimore, MD; August 18, 2018.
28. Donohoe KL, Van Tassell BW, Hylton-Gravatt LA, Brophy DF, Brophy GM, Bucheit JD, Caldas L, Crouse EL, **Dixon DL**, Flurie R, Gatewood SS, Goode JVR, Grecheck L, Kirkwood C, Matulewicz AT, McRae MP, Morgan LM, Omecene N, Pakyz AL, Powers KE, Peron EP, Sisson E, Slattum PW, Washington CS, Yunker NS, Zimmerman K. Evaluation of Disease

State Topics Taught in a Doctor of Pharmacy Curriculum Using the ACCP Toolkit. American Association of Colleges of Pharmacy Annual Meeting; Boston, MA; July 22, 2018. *Am J Pharm Educ.* 2018;82(5):510.

27. Bajaj S, Lajthia E, **Dixon DL**, Salgado TM. Pharmacy Practice Innovation Research Centers Across the United States. American Pharmacists Association Annual Meeting; Nashville, TN; March 2018. *J Am Pharm Assoc.* 2018;58(2):e182.

25. Van Tassell BW, Wohlford G, Kim F, Canada J, Carbone S, Kadariya D, Billingsley H, Trankle C, Buckley L, **Dixon D**, Viscusi M, Del Buono M, Medina H, Arena R, Abbate A. Interleukin-1 Blockade Reduces Patient Perceptions of Exertion and Dyspnea Among Patients with Recently Decompensated Systolic Heart Failure: A Subgroup Analysis of the REDHART Trial. American College of Cardiology Scientific Sessions; Orlando, FL; March 2018. *J Am Coll Cardiol.* 2018;71(11): Suppl 1: A968.

25. Van Tassell B, Canada J, Buckley L, Carbone S, Trankle C, Del Buono M, **Dixon D**, Kadariya D, Billingsley H, Park TS, Vo Chau, Dessie S, Arena R, Abbate A. Interleukin-1 Blockade in Heart Failure with Preserved Ejection Fraction: The Diastolic Heart Failure Anakinra Response Trial 2 (DHART2). American Heart Association Scientific Sessions; Anaheim, CA; November 2017. *Circulation.* 2017;136 (Suppl 1):A177709.

24. ****Buckley LF, Dixon DL**, Wohlford GF, Wijesinghe D, Baker WL, Van Tassell BW. Intensive Blood Pressure Control in Patients with and without Type 2 Diabetes Mellitus: An analysis of SPRINT and ACCORD BP. American College of Clinical Pharmacy Annual meeting; Phoenix, AZ; October 2017. *Pharmacotherapy.* 2017;37(12):e143.

Recognition: Best Resident/Fellow Poster Award

23. Carbone S, Canada JM, Buckley LF, Trankle C, Giuseppe MG, **Dixon DL**, Kiadariya D, Billingsley H, Park TS, Vo C, Dessie SA, Buzzetti R, Arena R, Van Tassell BW, Abbate A. BMI is an Independent Determinant of Exercise Intolerance in Obese Patients with HFpEF. Obesity Week Annual Conference. Washington, DC; November 2, 2017.

22. ****Helsing H, Taylor P, Dixon D**. Practice Patterns for Addressing LDL-Cholesterol Levels Below 40 in Patients Receiving Statin Therapy. National Lipid Association Annual Scientific Sessions; Philadelphia, PA; May 2017. *J Clin Lipidol.* 2017; 11(3):835. American College of Clinical Pharmacy Virtual Poster Symposium; May 2017. *Pharmacotherapy.* 2017;37(6):e40.

Recognition: 2nd Place, Best Poster Award (Ambulatory Care PRN)

21. ****Parod E, Dixon DL**, Sisson E, Nadpara P, Van Tassell B, Carl D, Dow A. Comparison of a Pharmacist-Physician Collaborative Care Model to Standard Care on the Time to Reach Goal Blood Pressure for Patients with Hypertension. American College of Cardiology Annual Meeting; Washington, DC; March 2017. *J Am Coll Cardiol.* 2017; 69(Suppl II):2566.

Recognition: Honorable Mention Award (Outcomes Research Category)

20. **Dixon DL**, Parod E, Sisson E, Nadpara P, Van Tassell B, Carl D, Dow A. Comparison of a Pharmacist-Physician Collaborative Care Model to Standard Care on the Time to Reach Goal Blood Pressure for Patients Presenting with Urgent Hypertension. American College of Cardiology Annual Meeting; Washington, DC; March 2017. *J Am Coll Cardiol.* 2017; 69(Suppl II):1837.

19. **Dixon DL**, Trankle C, Buckley L, Carbone S, Abbate A. Management of Obesity in Patients with Diastolic Dysfunction. American College of Cardiology Annual Meeting; Washington, DC; March 2017. *J Am Coll Cardiol.* 2017; 69(Suppl II):2106.

18. Buckley LF, Carbone S, Canada J, Trankle C, Christopher S, Regan J, Viscusi MM, **Dixon DL**, Abouzaki A, Kadariya D, Arena R, Abbate A, Van Tassell B. Arterial elastance drives ventilator inefficiency in systolic heart failure. American College of Cardiology Annual Meeting; Washington, DC; March 2017. *J Am Coll Cardiol.* 2017; 69(Suppl II):746.

17. Trankle C, Canada J, Buckley L, Carbone S, **Dixon D**, Arena R, Van Tassell B, Abbate A. Early diastolic mitral annular velocity at peak exercise determines peak aerobic exercise capacity in heart failure with preserved ejection fraction. American College of Cardiology Annual Meeting; Washington, DC; March 2017. *J Am Coll Cardiol.* 2017; 69 (Suppl II):889.

16. Carbone S, Canada JM, Buckley LF, Trankle CR, Billingsley H, Dessie S, Kadariya D, Abouzaki NA, Thurber C, **Dixon D**, Buzzetti R, Van Tassell BW, Abbate A. Sugar consumption predicts impaired cardiorespiratory fitness in patients with heart failure with preserved ejection fraction. ASPEN Nutrition Science and Practice Conference; Orlando, FL; January 2017. *J Parenter Enteral Nutr.* 2017;41(2): Suppl 1: 266-300.
15. Billingsley H, Carbone S, Buckley L, **Dixon D**, Kadariya D, Dessie S, Van Tassell BW, Abbate A, Siddiqui M. Dietary polyunsaturated fatty acid consumption is associated with improved body composition in nonalcoholic steatohepatitis patients. Association for Clinical and Translational Science Annual Meeting; Washington, DC; April 2017. *J Clin Transl Sci.* 2017;1(Suppl 1):38.
14. Buckley L, Carbone S, Trankle C, Viscusi MM, Regan J, **Dixon D**, Abouzaki N, Christopher S, Billingsley H, Kadariya D, Arena R, Abbate A, Van Tassell B. Ventriculo-arterial coupling and left ventricular mechanical work in systolic and diastolic heart failure. Association for Clinical and Translational Science Annual Meeting; Washington, DC; April 2017; *J Clin Transl Sci.* 2017;1(Suppl 1):36.
13. ****Parod E, Dixon D, Sisson E, Ogbonna K.** A case report of complete warfarin resistance and clinical application of pharmacogenetic testing. American College of Clinical Pharmacy Annual Meeting; Hollywood, FL; October 2016. *Pharmacotherapy.* 2016; 36(12):e297.
12. ****Parod E, Dixon D, Sisson E, Nadpara P, Moczygemba L, Carl D, Dow A.** Pharmacist-physician collaborative care model vs. standard card: assessing time to blood pressure goal. American College of Clinical Pharmacy Virtual Poster Symposium; May 2016. *Pharmacotherapy.* 2016;36(7):e112.

Recognition: Best Poster Award (Ambulatory Care PRN)

11. **Dixon DL**, Sisson EM, Parod E, Kelly M. Nighttime Dosing of Amlodipine vs. Lisinopril in Non-Dipping African Americans - an Interim Analysis. American Association of Colleges of Pharmacy Annual Meeting; Anaheim, CA; July 2016. *Am J Pharm Educ.* 2016;80(5) Article S2:119.
10. Chennault R, Touchette D, Ford KD, Capitano B, Welch V, Beck B, Bergman S, Bishop W, Bolesta K, Bratberg J, Cleary J, Das RP, Depcinski SC, **Dixon DL**, Engle A, Estrada SJ, Hachey Dm, Haftmann R, Hayney M, Hebner J, Hughes B, Ikwuagwu JO, Irwin AN, Jantz J, Jen SP, Krause T, Kuhn S, Lamb K, Liewer SE, McCoy C, McGuffey G, McKeen JT, McManus D, Morell J, Murray KP, Olin JL, Painter NA, Parish T, Peppard WJ, Porath A, Rudd KM, Swierz, Tran M, Wardlow LC, Wdowiarz K, White M, Yancey AM, Yeung SYA, Zarowitz BJ. American College of Clinical Pharmacy Practice-Based Research Network Collaborative: Navigating Institutional Review Board Challenges in a Clinical Pharmacy Practice-Based Research Study. North American Primary Care Research Group Practice-Based Research Network Conference; Bethesda, MD; June 29, 2015.
9. Kiser K, Haines S, **Dixon DL**, Tran A. iForumRx – Utilizing the World Wide Web to Connect Ambulatory Care Pharmacists. American College of Clinical Pharmacy Global Conference on Clinical Pharmacy; San Francisco, CA; October 2015. *Pharmacotherapy.* 2015; 35(11): e228-e229.
8. Sicat BL, **Dixon DL**, Bishop S, Lee B, Rybarczyk B, Stewart K, Wolver S, Phillips A. Interprofessional Team-Based Learning in a Primary Care Teaching Clinic: Focus on Obesity. American Association of Colleges of Pharmacy Annual Meeting; National Harbor, MD; July 2015. *Am J Pharm Educ.* 2015;79(4):63.
7. **Dixon DL**, Sisson EM, Shuford VP, Harpe SE. Use of Video Recorded Clinic Visits to Improve Assessment of Student Pharmacist Clinical Interviewing Skills. American Association of Colleges of Pharmacy Annual Meeting; Grapevine, TX; July 2014. *Am J Pharm Educ.* 2014; 78(5):138.
6. ****Bucheit J, Sisson E, Dixon DL.** Ambulatory blood pressure monitoring for measuring the effectiveness of amlodipine and hydrochlorothiazide in treating urgent and stage 2 hypertension. American College of Clinical Pharmacy Virtual Poster Symposium. *Pharmacotherapy.* 2014; 34(6): e101.
5. ****Ayele S, **Case B, **Dane K, **Jafari N, **Robinson M, **Tran N, Sisson E, Dixon DL.** Validation of the Medication

Adherence Individual Review Screening Tool in Underserved Adult Patients. American Society of Health-System Pharmacists Mid-Year Meeting; Anaheim, CA; December 2014.

4. Sisson E, **Dixon DL**, Kildow C. Evaluation of Comprehensive Medication Management in a Safety Net Clinic. Association of Diabetes Care & Education Specialists Annual Meeting; Orlando, FL; August 2014.

3. ****Kelly M, Dixon DL**. Interim Results from a Cardiologist-Pharmacist Collaboration to Improve Blood Pressure in an Ambulatory Cardiology Clinic. American College of Clinical Pharmacy Annual Meeting; Albuquerque, NM; October 2013. *Pharmacotherapy*. 2013; 33(10): e271.

2. ****Scott A, Sisson E, Pakyz A, Dixon DL**. Evaluation of Cardiometabolic Risk in an Underserved Population. American Society of Health-System Pharmacists Mid-Year Meeting; Orlando, FL; December 2013.

1. Williams V, **Dixon DL**, Barnette D, Beardsley J. Healthy Outcome Partnership for Employees with diabetes (HOPE): Evaluation of an Employer-Sponsored Diabetes Management Program. American College of Clinical Pharmacy Spring Practice & Research Forum; Charlotte, NC; April 2010. *Pharmacotherapy*. 2010;30(4): e153.

Local and Regional

7. ****Grigsby J, Patterson J, Gatewood S, Kaefer T, Jadallah J, Curtis M, Hawkey L, Salgado TM, Holdford D, Dixon DL**. Development of a 24-Hour Ambulatory Blood Pressure Monitoring Service in Community Pharmacy. 8th Annual Jewell and Carl F. Emswiler Interprofessional Symposium; Richmond, VA; February 29, 2020.

6. Morales J, Suarez N, Garcia J, Caldas L, Matulewicz A, Orengo S, Murchie M, Crossman S, Salgado T, **Dixon D**, Bucheit J. Comparison of Blood Pressure Control Rates in Patients with Type 2 Diabetes Mellitus Seen in an Interprofessional Clinic versus National Data. 8th Annual Jewell and Carl F. Emswiler Interprofessional Symposium; Richmond, VA; February 29, 2020.

5. Trankle C, Carbone S, Canada JM, *Buckley L, **Dixon DL**, Buzzetti R, Arena R, Van Tassell B, Abbate A. Obesity Contribute to Exercise Intolerance in Heart Failure with Preserved Ejection Fraction. Mid-Atlantic Capital Cardiology Symposium; Washington, DC; November 2016.

4. Sisson EM, **Dixon DL [Presenter]**, Kildow C, Van Tassell B, Carl DE, Varghese D, Electricwala B, Carroll N. Pharmacist Physician Collaboration to Improve Blood Pressure Control in an Inner City Safety-Net Clinic. Third Annual Jewell and Carl F. Emswiler Interprofessional Symposium; Richmond, VA; April 2015.

Recognition: Best Poster Award

3. **Dixon DL**, Sicat BL, Bishop S, Lee B, Rybarczyk B, Stewart K, Wolver S, Phillips A. Interprofessional Team-Based Learning in a Primary Care Teaching Clinic: Focus on Obesity. 3rd Annual Jewell and Carl F. Emswiler Interprofessional Symposium; Richmond, VA; April 2015.

2. Thomas CS, Trankle CR, Carbone S, Oddi C, Abouzaki NA, Turlington J, Melchior RD, **Dixon D**, Van Tassell BW, Abbate A. High risk clinical features of patients with systolic heart failure upon discharge after an episode of acute decompensation (from the VCU-RED-HEART Pilot data). Mid Atlantic Capital Cardiology Symposium; Washington, DC; November 2014.

1. Crossman S, Stevens M, Ryan M, Mack D, **Dixon DL [Presenter]**. Interprofessional Global Service Learning Through HOMBRE (Honduras Outreach Medical Brigade Relief Effort). 1st Annual Jewell and Carl F. Emswiler Interprofessional Symposium; Richmond, VA; April 2013.

INVITED PRESENTATIONS

International

1. *Cholesterol Vaccines or Extravagant Injectable Medications? An Update for Pharmacists*. PharmaCEries Webinars (Virtual). Cleveland

Clinic Abu Dhabi, UAE; June 21, 2022.

National

45. **[Guest Panelist]** “*ABCDs*” of *Managing Chronic Coronary Disease: Emerging Recommendations*. Prescriber’s Letter and Pharmacist’s Letter (Webinar); September 18, 2023.

44. *Medication Conundrum Cases*. American College of Cardiology Scientific Sessions; New Orleans, LA; March 2023.

43. *Inclisiran: When and How Should We Use It?* American College of Cardiology Scientific Sessions; New Orleans, LA; March 2023.

42. *Overview of New Pharmacologic Therapies for Heart Failure*. American College of Cardiology Scientific Sessions; Washington, DC; April 2022.

41. *Therapeutic Inertia: Strategies to Achieve Treatment Goals Utilizing Team Based Care*. American College of Cardiology Scientific Sessions; Washington, DC; April 2022.

40. **[Panelist]** *Finding the Sweet Spot for SGLT2 and GLP-1 Use in Cardiovascular Prevention*. American College of Cardiology Scientific Sessions; Washington, DC; April 2022.

39. Co-presented with Joseph Saseen, PharmD. *Old Drugs, New Drugs, and New Evidence for Dyslipidemia Management*. American Society of Health System Pharmacists Midyear Clinical Meeting (Virtual); December 2021.

38. **[Moderator]** *A Cornucopia of Cardiovascular Therapies: Ripe for the Picking or Too Much of a Good Thing?* American College of Clinical Pharmacy Annual Meeting (Virtual); November 17, 2021.

37. *Pharmacotherapy for Weight Loss: When and How*. American College of Cardiology Scientific Sessions (Virtual); May 2021.

36. *Under Pressure: How to Write Recommendation Letters that Stand Out from the Pack*. American College of Clinical Pharmacy Spring Forum (Virtual); April 2021.

35. *Scholarship in the 21st Century: Optimizing Reach, Engagement, and Impact*. American College of Clinical Pharmacy Annual Meeting (Virtual); October 2020.

34. Co-Presented with Mark Cziraky, PharmD, Lynne Braun, NP, and Harold Bayes, MD. *Tailoring Lipid-Lowering Therapy to Meet Individualized Goals*. A Medscape Live! Event (Webinar); September 10, 2020.

33. Co-Presented with Joseph Saseen, PharmD and Karen Aspry, MD. *Lipid Logic – Guess the Answer: An Interactive Audience Session*. National Lipid Association (Webinar); September 10, 2020.

32. *Cardiovascular Patient Management in the Era of COVID-19*. National Lipid Association (Webinar); May 22, 2020.

31. *Increasing Access to 24-hour Ambulatory Blood Pressure Monitoring Through Community Pharmacies*. American Pharmacists Association Meeting; Washington, DC; March 21, 2020. **(Conference canceled due to COVID-19)**

30. *Overview of Pre-DM and Metabolic Syndrome and ASCVD Risk*. American College of Cardiology Annual Scientific Session; Chicago, IL; March 29, 2020. **(Conference canceled due to COVID-19)**

29. *Pharmacology for The Clinician: SGLT-2 Inhibitors & GLP-1 Agonists*. American College of Cardiology Annual Scientific Session; Chicago, IL; March 28, 2020. **[Session Co-Chair] (Conference canceled due to COVID-19)**

28. *Evaluating the Updated 2018 ACC/AHA Cholesterol Guidelines*. American College of Clinical Pharmacy Annual Meeting; New York City, NY; October 27, 2019.

27. *Navigating the Jungles of Vascular Outcomes*. American College of Clinical Pharmacy Annual Meeting; New York City, NY;

October 26, 2019.

26. *Understanding the Real-World Uses of Drug Interaction Information*. U.S. Food & Drug Administration Section 7 Labeling: Enhancing the Accessibility and Utility of Drug Interaction Information Private Stakeholder Workshop; Washington, DC; October 16, 2019. Organized by the Duke-Margolis Center for Health Policy. Policy brief from the workshop published [online](#).

25. *Implementation of Team-Based Strategies to Improve Hypertension Outcomes*. 3rd Annual University of Utah Translational Hypertension Symposium and Early Stage Investigator Workshop; Salt Lake City, Utah; October 10, 2019. Sponsored by the National Heart, Lung, and Blood Institute (R13HL144012-2).

24. **[Moderator]** *Mythbusters in Clinical Lipidology – Pharmacotherapy Debunked*. National Lipid Association Annual Scientific Sessions; Miami, FL; May 18, 2019.

23. *State of the Art Case-Based Lecture: Individualizing the Process of Prescribing Through Shared-Decision Making*. American College of Cardiology Annual Meeting; New Orleans, LA; March 16, 2019.

22. *Risk-Based Hypertension Management: It's All About Context!* American College of Cardiology Annual Meeting; New Orleans, LA; March 16, 2019.

21. *How Well Do You Know Your Drug-Drug Interactions? A Case-Based Lecture*. American College of Cardiology Annual Meeting; New Orleans, LA; March 17, 2019.

20. *An Evidence-Based Approach to Using Social Media to Enhance Your Scholarly Career*. American College of Clinical Pharmacy Global Conference on Clinical Pharmacy; Seattle, WA; October 23, 2018.

19. *Establishing Your Digital Profile: Your Guide to Twitter and LinkedIn*. American College of Clinical Pharmacy Global Conference on Clinical Pharmacy; Seattle, WA; October 22, 2018.

18. Co-presented with Melissa Magwire, RN and Lauren Pamulapati, PharmD. *Contemporary Approaches to Managing Diabetes in Individuals with Cardiovascular Disease*. Association of Diabetes Care & Education Specialists Annual Meeting; Baltimore, MD; August 19, 2018.

17. Co-presented with Amber Martirosov, PharmD. *PCSK9 Inhibitors: Appropriate Use in Patients with Atherosclerotic Cardiovascular Disease*. American Society of Health-System Pharmacists Summer Meeting; Denver, CO; June 3, 2018.

16. *Dyslipidemia*. Cardiology Pharmacy Preparatory Review Course. American College of Clinical Pharmacy Updates in Therapeutics; Jacksonville, FL; February 16, 2018.

15. *Managing Diabetes in Patients with Cardiovascular Disease and Heart Failure*. Novo Nordisk Diabetes Educator Training Program provided by the Association of Diabetes Care & Education Specialists (Webinar); December 1, 2017.

14. *New Technologies in Development for Targeting PCSK9: What's on the Horizon?* National Lipid Association Clinical Lipid Update Meeting; Indianapolis, IN; August 12, 2017.

13. **Co-Session Chair** with Joyce Ross, NP. *Back to the Future: Clinical Experience with and Access to Lipid-Lowering Agents of the Past, Present, and Future*. National Lipid Association Expert Discussion and Town Hall. Scientific Sessions Meeting; Philadelphia, PA; May 18, 2017.

12. *Therapeutic Options for Managing Hypertriglyceridemia*. National Lipid Association Clinical Lipid Update Meeting; Amelia Island, FL; August 26, 2016.

Press Coverage: Lipid Luminations on ReachMD (podcast). [Triglyceride-Lowering Therapies: Addressing Gaps in the Guidelines](#). A. Brown. September 26, 2016.

11. *Nuts and Bolts of the New Anti-Obesity Drugs and Which One for Who? Pharmacology, Drug-Drug Interactions, and Efficacy*. American College of Cardiology Annual Meeting; Chicago, IL; April 3, 2016.

Press Coverage

- MD Magazine (video interview). [No Magic Pill in Treatment of Obesity](#). A. Hochron. April 13, 2016.
- ACC Extended Learning, Cardiology Magazine (interview). [Nuts and Bolts of the New Anti-obesity Drugs: Pharmacology, Drug-Drug Interactions, and Efficacy](#). CN Bairey-Merz. 2017;42(2):20-21.

10. *Team-Based Care Cardiovascular Care: A Unified Vision to Improve Patient Care*. American College of Cardiology Scientific Sessions; Chicago, IL; April 3, 2016.

9. *Latest Developments in Insulin Therapy*. Association of Diabetes Care & Education Specialists (Webinar); August 19, 2015.

8. Co-Presented with Evan Sisson, PharmD. *Lipid Guidelines: What is Best for My Patient?* Association of Diabetes Care & Education Specialists Annual Meeting; New Orleans, LA; August 5, 2015.

Press Coverage: Endocrine Today: Highlights from ADCES 2013 (quote). [Individualization key to cholesterol management](#). August 9, 2013.

7. *Endocrine Update*. American Society of Consultant Pharmacists Certified Geriatric Pharmacist Exam Preparation and Recertification Boot Camp; Baltimore, MD; August 1, 2015.

6. *Cardiovascular Update*. American Society of Consultant Pharmacists Certified Geriatric Pharmacist Exam Preparation and Recertification Boot Camp; Baltimore, MD; August 1, 2015.

5. Co-Presented with Andrew Bzowyckj, PharmD, Ginah Nightingale, PharmD, Mary Vilay, PharmD. *Tips on Being a Successful New Investigator Award Recipient*. American Association of Colleges of Pharmacy (Webinar); June 10, 2015.

4. Co-Presented with Frank Zieve, MD. *Dyslipidemia in FQHCs: Rising to the Challenge*. National Lipid Association (Webinar); March 16, 2015.

3. *Use of Video Recorded Clinic Visits to Improve Assessment of Student Pharmacist Clinical Interviewing Skills*. American Association of Colleges of Pharmacy Annual Meeting; Grapevine, TX; July 29, 2014.

2. **[Moderator]** *Case Based Workshop: Atrial Fibrillation Monitoring and Management*. National Association of Specialty Pharmacy (Webinar); March 26, 2014.

1. Co-Presented with Evan Sisson, PharmD. *New Lipid Guidelines, Were they Worth the Wait?* Association of Diabetes Care & Education Specialists Annual Meeting; Philadelphia, PA; August 8, 2013.

Local and Regional

34. *Clinical Management of Heart Failure in 2023: Guideline Updates*. A Contemporary Approach to Heart Failure: Updates for the Cardiology Advanced Practice Provider; Richmond, VA; November 18, 2023

33. *Dyslipidemia Management in Women Requires a Scalpel, not a Sledgehammer*. Heart Health in Women 2022 Conference; Richmond, VA; February 5, 2022.

32. *A Brief Review of the 2021 ADA Standards of Medical Care for Diabetes*. Practical Endocrine Topics for Primary Care (Virtual); June 5, 2021.

31. *Diabetes Management for the Cardiologist: No Longer Taboo!* Cardiology Fellow Case Conference. VCU Medical Center; Richmond, VA; October 6, 2020.

30. *Overview of Pharm.D. Education and Training for HB1506*. Commonwealth of Virginia Board of Pharmacy Statewide Protocol Workgroup Meeting (Virtual); August 3, 2020.
29. Co-presented with Ajay Pillai, MD and Antonio Abbate, MD. *Cardiovascular Manifestations of COVID-19*. Hospitalist Grand Rounds. VCU Medical Center; Richmond, VA; April 30, 2020. Encore presentation on May 18, 2020.
28. *Utilization of Pharmacy Residents and Dietetic Interns to Deliver a Diabetes Prevention Program to Underserved Patients*. 8th Annual Jewell and Car F. Emswiler Interprofessional Symposium; Richmond, VA; February 29, 2020.
27. *APhA Pharmacy-Based Cardiovascular Disease Risk Management Course*. Virginia Pharmacists Association Annual Meeting; Virginia Beach, VA; August 18, 2019.
26. Co-presented with Stephanie Mayer, MD. *Update on clinical management of hyperlipidemia*. Practical Endocrine Topics for Primary Care Symposium. Richmond, VA; June 8, 2019.
25. Co-presented with Stephanie Mayer, MD. *Type 2 diabetes management beyond A1c – oral medications and non-insulin therapy*. Practical Endocrine Topics for Primary Care Symposium. Richmond, VA; June 8, 2019.
24. Co-presented with Leticia Moczygomba, PhD. *Implementation Strategies*. 7th Annual Jewell and Carl F. Emswiler Interprofessional Symposium: Pre-Conference on Best Practices for Implementing Team Based Primary Care. Richmond, VA; February 1, 2019.
23. *Elevated Triglycerides and Residual Cardiovascular Risk: Much Ado About Nothing?* Cardiology Grand Rounds. VCU Medical Center; Richmond, VA; August 9, 2018.
22. *Which non-statin (if any) is right for my patient?* Pharmacotherapy Grand Rounds. VCU Medical Center; Richmond, VA; February 1, 2018.
21. *Update in Cardiovascular Pharmacotherapy*. Virginia Association of Clinical Nurse Specialists Annual Pharmacology Conference; Richmond, VA; September 29, 2017.
20. *Dyslipidemia Management: Past, Present, and Future*. Cardiology Grand Rounds. VCU Medical Center; Richmond, VA; August 17, 2017.
19. Co-Presented with Salvatore Carbone, MS and Antonio Abbate, MD, PhD. *SGLT2 Inhibitors for the Prevention of Cardiovascular Events in Diabetes*. Department of Internal Medicine Grand Rounds. VCU Medical Center; Richmond, VA; May 22, 2017.
18. *2013 ACC/AHA Cholesterol Guideline: Has the dust finally settled?* Cardiology Grand Rounds. VCU Pauley Heart Center; Richmond, VA; August 25, 2016.
17. **[Panelist]** *Reflections on Current Admissions Practices*. VCU Health Admissions Symposium; Richmond, VA; May 23, 2016.
16. *Contemporary Diabetes Management: “Out with the Old, in with the New?”* Cardiology Case Conference. VCU Pauley Heart Center; Richmond, VA; May 12, 2016.
15. **[Panelist]** *Clinician or Researcher: Why not both?* Ready, Set, Grant! Workshops on Competitive Grant Writing. VCU Health System; Richmond, VA; January 12, 2016.
14. Co-Presented with Lana Konigsberg, PharmD. *Educational Roundtable Discussion: Familial Hypercholesterolemia*. Sponsored by Sanofi U.S.; Richmond, VA; October 13, 2015.
13. *Review of ACC/AHA Guidelines on Lipid Management*. VCU Pauley Heart Center Core Conference for Cardiology Fellows; Richmond, VA; August 18, 2015.

12. **[Panelist]** *The Voices of Primary Care Collaborators*. VCU Department of Family Medicine and Population Health, Student Family Medicine Association; Richmond, VA; October 11, 2014.
11. Co-Presented with Lana Konigsberg, PharmD. *Educational Roundtable Discussion: Unmet Needs in Hyperlipidemia*. Sponsored by Sanofi U.S.; Richmond, VA; August 7, 2014.
10. *Implications of the 2013 Cholesterol Guideline...Myth vs. Reality*. Virginia Pharmacists Association 133rd Annual Convention; Virginia Beach, VA; August 4, 2014.
9. *The Quandary of QT_c Prolongation*. 25th Annual Virginia Geriatrics Conference; Richmond, VA; April 25, 2014.
8. Co-Presented with Lana Konigsberg, PharmD. *Educational Roundtable Discussion: Unmet Needs in Hyperlipidemia*. Sponsored by Sanofi U.S.; Richmond, VA; April 8, 2014.
7. *Hypertension Treatment Across the Lifespan*. Virginia Dietetic Association Meeting; Richmond, VA; April 7, 2013.
6. *Implications of the 2013 ACC/AHA Lipid Management Guidelines*. Campbell University College of Pharmacy & Health Sciences Alumni Event; Concord, NC; March 2, 2014.
5. *Update on Lipid Management – Where are we now?* Virginia Chapter of the American College of Cardiology, Annual Meeting; Richmond, VA; October 4, 2013.
4. *Management of Hypertension Across the Lifespan*. VCU Health System Advanced Practice Nurse Conference; Richmond, VA; April 19, 2013.
3. **[Panelist]** *If I Knew Then What I Know Now: Sound Advice from Early Career Faculty*. VCU Center for Teaching Excellence; Richmond, VA; August 12, 2013.
2. Co-Presented with Kristin Duffey, PharmD. *2007 New Drug Update*. Western NC Pharmacy Association; Asheville, NC; February 18, 2007.
1. *A Review of Hypertension*. Mountain Area Health Education Center; Asheville, NC; September 2006.

ONLINE AND TRADE JOURNAL PUBLICATIONS (mentee)**

23. Jones PH, Wilson DP, **Dixon DL**, Deville C. NLA's Future Education Endeavors. *Lipid Spin: Here and Now*. 2022; 2-4.
22. **Dixon DL**, Underberg J. The Future of NLA Scientific Statements: To Infinity and Beyond! *Lipid Spin: Here and Now*. 2022; 12-13.
21. ****Gaine SP**, Kulkarni A, **Dixon DL**, Patel J. Expert Analysis: NLA 2022 Definition of Statin Intolerance. American College of Cardiology. [Available here](#). Aug 17, 2022.
20. ****Farbaniec M**, Hartz J, Singh A, **Dixon DL**. Expert Analysis: Utilization of Clinical Testing in the Setting of Dyslipidemia. American College of Cardiology. [Available here](#). Nov 22, 2021.
19. ****Sharif M**, Patel J, Al Rifai M, **Dixon DL**, Shapiro MD. Expert Analysis: One Pill for Them All: Polypill Therapy for the Prevention of Cardiovascular Disease. American College of Cardiology. [Available here](#). Mar 19, 2021.
[Selected as an Editor's Pick]
18. ****De Jesus C**, Teasley B, **Dixon DL**, Bucheit JD. Patient Case Quiz: ASCVD Risk Reduction in a Patient with Familial Hypercholesterolemia. American College of Cardiology. [Available here](#). August 4, 2020.
17. ****Saeed A**, **Dixon DL**, Yang E. Expert Analysis: Racial Disparities in Hypertension Prevalence and Management: A Crisis

Control? [Available here](#). Apr 6, 2020.

16. ****Patel J, Al Rifai M, Dixon DL, Shapiro MD.** Patient Case Quiz: Primary Prevention of Atherosclerotic Cardiovascular Disease for Those at Intermediate Risk. [Available here](#). April 3, 2020.
15. Wiggins B, **Dixon D.** Smoking Cessation: It's a Team Sport. *Lipid Spin*. 2019;17(3):25-27.
14. ****Anderson A, Caldas L, Dixon DL.** LDL Limbo: How Low is Too Low? iForumRx. [Available here](#). October 26, 2018.
13. **Dixon DL.** The PREDIMED Study: Should the Mediterranean Diet be Recommended to Prevent Cardiovascular Disease? *Lipid Spin* 2017;15(4):20-21.
12. ****Buckley L, Dixon DL.** Are Statins “ALL-THAT” for Primary Prevention in Older Adults? A Second Look at ALLHAT LLT. iForumRx. [Available here](#). August 25, 2017.
11. Croy DS, **Dixon DL, Kennedy L.** Dyslipidemia & Antipsychotic Medications: Who is Monitoring the Lipids? *Lipid Spin* 2016; 14(2):7-9.
10. **Dixon DL, Sisson EM.** Lipid Illuminations: HPS2-THRIVE Commentary. *Lipid Spin* 2015; 13(1):16-17.
9. **Dixon DL, Sisson EM.** Ten Things Every Clinician Should Know About the 2013 ACC/AHA Lipid Guidelines. iForumRx. [Available here](#). November 26, 2013.
8. **Dixon DL, Bolick JP, Godishala LM, Kris-Etherton PM, Nash DT, Neri L, Warren WS.** Clinician's Toolkit: A Guide to Medication and Lifestyle Adherence. *Lipid Spin* 2013; 11(Suppl1):1-20.
7. ****Siskey J, Lyles A, Dixon DL.** Beta-Blockers and Hypertension, Where is the Data? iForumRx. Link not available. 2012.
6. ****Coles T, Dixon DL.** Another Bust for Omega-3 Fatty Acids – Is it Time to Go Fishing Elsewhere? iForumRx. [Available here](#). October 2012.
5. **Dixon DL.** Exenatide Before Prandial Insulin? – Not Just Yet! iForumRx. [Available here](#). February 2012.
4. **Dixon DL.** Venous Thromboembolism Prophylaxis in Patients with Multiple Myeloma. *U.S. Pharm.* 2013;38(3)(Oncology suppl):8-11.
3. **Dixon DL.** Hypertriglyceridemia Management in Patients with Diabetes. *U.S. Pharm.* 2009; 34(5)(Diabetes suppl):3-6.
2. **Dixon DL, Kim J.** Pharmacology Consult: The Current Status of Amiodarone Adverse Event Monitoring. *Cardiology Today*. 2014;16(12):32.
1. **Dixon DL.** Stroke and TIAs – Minimizing the Risk of Recurrence. *Pharmacy Times*. Dec 2009;64-66.

PUBLISHED PROFESSIONAL EDUCATION PROGRAMS

12. *Understanding the Challenges of Homozygous Familial Hypercholesterolemia.* Pharmacy Times CE. Published [online](#) July 2023.
11. *The Impact of PCSK9 Modulation on Cardiovascular Outcomes: Recent Advances and the Managed Care Implications.* Pharmacy Times CE. Published [online](#) October 2022.
10. *NLA Scientific Statement on Statin Intolerance: A New Definition and Guidance on Managing Statin Intolerant Patients* [Tweeetorial]. Cardiometabolic Medicine CME. Published [online](#) July 2022.
9. Croy D, **Dixon D, Lundberg G.** *Guideline Education: Lp(a) Is an Important Risk Marker to Prevent Coronary Artery Disease.* American

College of Cardiology. Published [online](#) October 2019.

8. *2018 Update on Cholesterol Management and ASCVD Risk Reduction*. American Pharmacists Association. February 2019.

7. Co-Presented with Rhonda Cooper-DeHoff. *A Pharmacist's Guide to PCSK9 Inhibitors: From Patient Selection to Pharmacoeconomics*. Medscape Education. Published [online](#) December 2016.

6. *Cardiovascular Disease: Peripheral Arterial Disease*. Certified Geriatric Pharmacist (CGP) Review. American Society of Consultant Pharmacists. Published [online](#) October 2015.

5. *Cardiovascular Disease: Cardiac Arrhythmias*. Certified Geriatric Pharmacist (CGP) Review. American Society of Consultant Pharmacists. Published [online](#) October 2015.

4. *Cardiovascular Disease: Heart Failure*. Certified Geriatric Pharmacist (CGP) Review. American Society of Consultant Pharmacists. Published [online](#) October 2015.

3. *Arrhythmias in the Older Adult*. Certified Geriatric Pharmacist (CGP) Review. American Society of Consultant Pharmacists. Published [online](#) August 2015.

2. *Demystifying Metformin*. Foundation for Health Improvement & Technology: LecturePad.org. Published [online](#) January 10, 2015.

1. *Management of Hypertension Across the Lifespan*. Foundation for Health Improvement & Technology: LecturePad.org. Published [online](#) October 30, 2013.

PUBLIC MEDIA QUOTES AND INTERVIEWS

27. Quoted in Medpage Today: [Statins Reach More Patients With Pharmacist's Orders – Asynchronous automated order approach boosts statin prescribing](#). N. Lou. November 14, 2023.

26. Quoted in tctMD: [Similar Outcomes With Enteric-Coated and Uncoated Aspirin: ADAPTABLE](#). T. Neale. October 6, 2023.

25. Interviewed on iForumRx Podcast: [Beyond Statins: Approaches to Lipid Lowering in 2023](#). September 5, 2023.

24. Interviewed on Pharmacy To Dose: The Critical Care Podcast: [HFpEF and Guideline/Consensus Document Writing](#). August 17, 2023.

23. Interviewed on Pharmacy Quality Solutions Quality Corner Show Podcast: [Aren't All Pharmacists Clinical?](#) August 1, 2023

22. Quoted in tctMD: [Migraine With Aura Doesn't Hone CV Risk Prediction in Middle-Aged Women](#). C. Cox. June 8, 2023.

21. Interviewed on Clinically Speaking! Podcast: Lipid Management: Advances in Treatment Options (link is private). D. Aistrophe. April 27, 2023.

20. Quoted in tctMD: [Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study](#). T. Neale. March 11, 2023

19. Quoted in Pharmacy Learning Network (Talking Therapeutics): [High-Density Lipoprotein: Too Much of a Good Thing?](#) D. Jennings. January 26, 2022.

18. Interviewed on Diverse Conversations Podcast: [The Future of Pharmacy with Dr. Dave Dixon](#). A. Patel. October 28, 2021.

17. Interviewed by VCU Health News: [COVID-19 and high blood pressure: Cause for concern?](#) K. Solberg. May 19, 2021.

16. Interviewed by VCU Health Bolus Podcast: Flozin-palooza: How SGLT2 Inhibitors Are Changing Management of Diabetes and More (link not available). A. Dow. December 10, 2020.

15. Interviewed by CardioScripts Podcast: [The EVAPORATE Trial](#). L. Sulaica. November 10, 2020.
14. Quoted in Virginia Mercury: [Virginia pharmacists report growing demand for experimental COVID-19 medications](#). K. Masters. March 27, 2020.
13. Quoted in Cardiology Today: [Perspective on: Meta-analysis provides new insights on CV risk with rosiglitazone](#). D. Dobkowski. February 13, 2020.
12. Interviewed by CardioScripts Podcast: [Plenty of fish \[oil\] in the sea, have we REDUCEd-IT to one?](#) L. Sulaica. January 28, 2020.
11. Quoted in Pharmacy Today: Confused about statin benefits? New AHA statement has answers. L. Bonner. March 2019;25(3):19.
10. Interviewed on Richmond's Morning News on WRVA 1140 (radio): No more preventive aspirin? March 19, 2019.
9. Interviewed by VCU Health Twitter Chat: New Blood Pressure Guidelines. A. Dreyfuss. February 26, 2018.
8. Interviewed by Men's Health: [7 Drugs You're Taking That Might Be Wrecking Your Workout](#). M. Taylor. August 29, 2017.
7. Interviewed by VCU Health GenMed Podcast: [Episode 30: SGLT2 Inhibitors, Prevention of Cardiovascular Events in Diabetes](#). July 19, 2017.
6. Quoted in Pharmacy Today: PCSK9 inhibitor prescriptions require extra resources. L. Bonner. August 2017;23(8):40.
5. Interviewed by Jimmy Barrett Show on WRVA 1140 (radio). Statins for More People. July 16, 2015.
4. Interviewed by VCU Health Twitter chat: New Developments in Cholesterol-Lowering Medications. June 29, 2015.
3. Quoted in Richmond Times-Dispatch: Your Health: [Pharmacies that dispense heart rhythm drug require special certification](#). T. Smith. June 22, 2014.
2. Quoted in MedPage Today: LDL No Longer Target of Kidney Disease Lipid Management. T. Neale. December 9, 2013.
1. Quoted in Bloomberg News: Annual Doctor Visits Will Increase Cholesterol Drug Use. M. Cortez. November 14, 2013.

OTHER SCIENTIFIC & SCHOLARLY ACTIVITIES

Professional Advisory Boards & Consultantships

| | |
|---|------------------------------|
| Subject Matter Expert (Hypertension), Community Pharmacy Enhanced Services Network (CPESN) | 2019-2020 |
| Consultant, Cardiology – Wolters Kluwer (Lexi-Comp) | 2018-2019 |
| Invited Attendee, CVD Risk Communication for Patients and Their Clinicians (hosted by the American College of Cardiology; Washington, DC) | Oct 17, 2018 |
| Invited Representative for ACCP, Effective Prior Authorization: Right Drug, Right Patient for Cardiovascular Treatment (hosted by the American College of Cardiology; Washington, DC) | Oct 12, 2017 |
| Invited Attendee, Managing Cardiovascular Risk in Diabetes (hosted by the American College of Cardiology; Washington, DC) | Dec 3, 2018 June 20, 2017 |

Invited Attendee, Cardiometabolic Think Tank (hosted by the American College of Cardiology & CardioMetabolic Health Alliance; Washington, DC)

June 20, 2014

Data Safety Monitoring Boards and Stakeholder Representative Work

Stakeholder Representative on behalf of the American College of Cardiology for a PCORI-sponsored observational study, BESTMED: oBservational Evaluation of Second line Therapy MEdications in Diabetes, PI: Alexander Turchin, MD, MS (Harvard University) July 2021-Present

Member, DSMB for NIH-sponsored clinical trial, Phase Ib/2a drug-drug interaction study of lemborexant as an adjunctive treatment for buprenorphine/naloxone for opioid use disorder, PI: F. Gerald Moeller, MD, PhD (VCU School of Medicine) Feb 2021-Present

Member, DSMB for NIH-sponsored clinical trial, Phase I Functional magnetic resonance imaging (fMRI) pharmacodynamic studies of compounds for Opioid Use Disorder and Cocaine Use Disorder, PI: F. Gerald Moeller, MD, PhD (VCU School of Medicine) July 2019-Aug 2020

Member, DSMB for NIH-sponsored clinical trial, 5-HT_{2A}R: 5HT_{2CR} Balance in Brain Connectivity in Cocaine Dependence, PI: F. Gerald Moeller, MD, PhD (VCU School of Medicine) July 2019-Aug 2020

Editorial Activities

Associate Editor

- *Journal of Clinical Lipidology* Feb 2021-Present
- *Journal of the American Pharmacists Association* Dec 2019-Present
- *PLoS One* 2018-2019

Section or Series Editor

- *Journal of Cardiovascular Pharmacology* Feb 2020-Feb 2022
- *ACCP Ambulatory Care Self-Assessment Panel (ACSAP)* 2017-2021

Social Media Editor

- iForumRx.org 2014-2016

Editorial Boards

- *Diabetes/Metabolism: Research and Reviews* 2020-Present
- ACC.org Pulse Check 2019-2021
- ACC.org Cardiovascular Team 2015-2017
- iForumRx.org 2013-2016
- *Journal of Clinical Lipidology* 2008-2021

Ad Hoc Peer Review (selected list of journals)

- *Circulation, Circulation: Cardiovascular Quality and Outcomes, European Heart Journal, European Heart Journal-Cardiovascular Pharmacotherapy, Journal of the American College of Cardiology, Clinical Cardiology, Pharmacotherapy, Journal of Clinical Hypertension, Journal of the American College of Clinical Pharmacy, American Journal of Health-System Pharmacists*

Clinical Practice Guideline Reviewer Activities

- Reviewer, on behalf of the Joint Committee on Clinical Practice Guidelines 2021 ACC/AHA Guideline for the Evaluation and Diagnosis of Chest Pain 2020
- Reviewer, on behalf of the Joint Committee on Clinical Practice Guidelines 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy 2020

- Reviewer, on behalf of the Joint Committee on Clinical Practice Guidelines 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease 2020
- Reviewer, on behalf of the National Lipid Association, 2018 ACC/AHA Guideline on the Management of Blood Cholesterol 2018
- Reviewer, on behalf of the American College of Cardiology, 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults 2017

Other Related Activities

Abstract Reviewer

- American Heart Association Hypertension Scientific Sessions 2020-2021
- National Lipid Association Scientific Sessions 2019-2021
- American College of Cardiology Scientific Sessions 2017-Present
- American College of Clinical Pharmacy Annual Meeting 2016-Present

Grant Reviewer

- ACC National Cardiovascular Data Registries: PINNACLE and Diabetes Collaborative 2019-2022
- AACP New Investigator Award 2019
- ACCP Cardiology PRN Seed Grant 2017-2019
- ACCP Ambulatory Care PRN Seed Grant 2012-2017

Conference Organizing Activities

- Diabetes Health Humanities Virtual Symposium. Sponsored by 4-VA. Hosted by James Madison University. Nov 20, 2020
- Pre-Conference Workshop: Best Practices for Implementing Team-Based Primary Care. 7th Annual Jewell and Carl F. Emswiler Interprofessional Symposium; Richmond, VA. Feb 1, 2019
- Pharmacist Training in Collaborative Care: Retooling for the Future. VCU Alumni House; Richmond, VA. June 9-10, 2017

TEACHING AND MENTORING EXPERIENCE

School of Pharmacy, Virginia Commonwealth University (*courses developed)

Course Coordinator

| | | |
|--|--------------------|------------------|
| Contemporary Pharmacy Practice (2.5 credits) | Required P1 course | Spring 2024 |
| *Patient Assessment in Pharmacy Practice (2 credits) | Required P2 course | Fall 2014 |
| *Advanced Cardiology (2 credits) | Elective P3 course | Spring 2013-2021 |
| Clinical Therapeutics Module: Cardiovascular (4.5 credits) | Required P2 course | Fall 2012-2020 |
| *Independent Research Elective (varies, 1-2 credits) | Elective P3 course | 2012-Present |

Lecturer / Instructor (topic, course)

| | | |
|---|--------------------|---------------------|
| Gout, Clinical Therapeutics Module: Women's Health/Bone | Required P3 course | Spring 2024 |
| Practice Guidelines, Evidence-Based Pharmacy III | Required P2 course | Spring 2023-Present |
| Dyslipidemia, Clinical Therapeutics Module: Cardiovascular | Required P2 course | Fall 2019-Present |
| Digital Communication, Communications & Health Promotion | Required P1 course | Fall 2019-2021 |
| Faculty Hiring, Evaluation, and Promotion, Academic Pharmacy | Elective P3 course | Fall 2018-Present |
| Information Mastery, Evidence-Based Pharmacy III | Required P2 course | Spring 2016-2017 |
| Scope of Practice, US Health Care System | Required P1 course | Fall 2016-2017 |
| Cardiovascular Assessment, Patient Assessment in Pharmacy Practice | Required P2 course | Fall 2015-2018 |
| Advanced Dyslipidemia, Advanced Cardiology | Elective P3 course | Spring 2013-Present |
| Complex Cardiology Cases, Complex Patient Therapeutics Module | Required P3 course | Spring 2013-2021 |
| Cardiac Arrhythmias, Cardiovascular Therapeutics Module | Required P2 course | Fall 2013-2020 |
| Collaborative Practice, Contemporary Pharmacy Practice | Required P1 course | Spring 2013 |
| Cardiology Literature Evaluation, Advanced Clinical Pharmacy Practice | Elective P3 course | Spring 2012 |

Small Group / Lab Facilitator

| | | |
|--|-----------------------|-------------------|
| Patient Assessment in Pharmacy Practice | Required P2 course | Fall 2014-Present |
| Evidence Based Pharmacy III – Drug Literature Evaluation | Required P2 course | Spring 2014-2021 |
| Foundations III, IV, V, VI | Required P1-P3 course | 2012-Present |

Primary Preceptor, Experiential Courses

| | | |
|--|---------------------|-------------------------|
| Tele-rotation during COVID-19 (121 students) | Required P4 courses | Apr/May 2020 |
| APPE, Ambulatory Care | Required P4 course | 2012-2018 |
| IPPE, Service Learning | Required P3 course | 2012-2018, 2022-Present |

Formal (Required) Student Mentoring

| | | |
|--|-----------------------|--------------|
| Continuous Professional Development Course | Required P1-P4 course | 2018-Present |
| Mentoring and Advising Program for Students (MAPS) | Required P1-P4 course | 2014-2017 |

College of Humanities and Science, Virginia Commonwealth University**Lecturer / Instructor (topic, course)**

| | | |
|---|-----------------|------------------|
| Obesity Pharmacotherapy, Nutrition for Health and Disease | Required course | Spring 2019-2021 |
|---|-----------------|------------------|

School of Nursing, Virginia Commonwealth University**Lecturer / Instructor (topic, course)**

| | | |
|---|-----------------|------------------|
| Atrial Fibrillation, Advanced Nursing Practice Pharmacotherapeutics | Required course | Spring 2013-2016 |
| Anticoagulation, Advanced Nursing Practice Pharmacotherapeutics | Required course | Spring 2013-2016 |
| Heart Failure, Advanced Nursing Practice Pharmacotherapeutics | Required course | Spring 2013-2016 |
| Interprofessional Practice, Concepts of Nursing | Required course | Spring 2013 |

Pharmacy Resident Precepting

| | | |
|---|-------------------|--------------|
| PGY-1/2 Academic Pharmacy Residency, VCU School of Pharmacy | Elective rotation | 2014-2019 |
| PGY-2 Ambulatory Care Residency, VCU School of Pharmacy | Required rotation | 2013-Present |
| PGY-2 Ambulatory Care Residency, VCU Health System | Elective rotation | 2012-Present |
| PGY-2 Internal Medicine Residency, VCU Health System | Elective rotation | 2012-Present |
| PGY-1 Pharmacy Practice Residency, VCU Health System | Elective rotation | 2012-Present |
| PGY-1 Pharmacy Practice Residency, Wake Forest Baptist | Elective rotation | 2007-2011 |

Notable Mentored Awards

| | | |
|--|--------------------------------|-------------------|
| Trevor Sproule (P2), PharmD Summer Fellowship Award (\$4,000) | VCU PharmD Student | Summer 2023 |
| Christine Tran (P3), Student Award (\$5,000), ACCP Futures Grant | VCU PharmD Student | Dec 2022-Dec 2023 |
| Christine Tran (P2), PharmD Summer Fellowship Award (\$4,000) | VCU PharmD Student | Summer 2021 |
| Teresa Salgado, Ph.D., K12 Mentored Training in Implementation Science Program, Washington University School of Medicine | VCU School of Pharmacy Faculty | 2020-2022 |
| Sarah Khaddage (P2), PharmD Summer Fellowship Award (\$4,000) | VCU PharmD Student | Summer 2020 |
| Alexandra Cox (P2), PharmD Summer Fellowship Award (\$4,000) | VCU PharmD Student | Summer 2019 |

Graduate Student Advisory Committees

| | | |
|--|-----------------|--------------|
| Khalifa Alrajeh, Primary advisor: Youssef Roman, Pharm.D., Ph.D. | Ph.D. Candidate | 2022-Present |
| Natalie Bohmke, Primary advisor: Danielle Kirkman, Ph.D. | Ph.D. Candidate | 2022-Present |
| Jessica Jay, Primary advisor: Julie Patterson, Pharm.D., Ph.D. | M.S. Candidate | 2021-2022 |
| Tyler Wagner, Primary advisor: Teresa Salgado, Ph.D. | Ph.D. Candidate | 2019-2023 |
| Rotana Radwan, Primary advisor: Teresa Salgado, Ph.D. | Ph.D. Candidate | 2019-2023 |

Post-Doctoral Fellows, Cardiovascular Pharmacotherapy Fellowship

| | | |
|--------------------------|-----------------|-----------|
| Ibrahim Alhomoud, PharmD | Primary Advisor | 2022-2023 |
|--------------------------|-----------------|-----------|

| | | |
|---|-------------------|-----------|
| Azita Talasaz, PharmD, Primary advisor: Ben Van Tassell, PharmD | Secondary Advisor | 2020-2023 |
| Ai-Chen Ho, PharmD, Primary advisor: Ben Van Tassell, PharmD | Secondary Advisor | 2019-2021 |
| George Wohlford, PharmD, Primary advisor: Ben Van Tassell, PharmD | Secondary Advisor | 2017-2020 |
| Leo Buckley, PharmD, Primary advisor: Ben Van Tassell, PharmD | Secondary Advisor | 2015-2017 |

PROFESSIONAL ORGANIZATION LEADERSHIP AND SERVICE ACTIVITIES

American College of Clinical Pharmacy (ACCP)

| | | |
|--------------|--|-----------|
| Member | Best Poster (Student) Judge Panel, Annual Meeting | 2023 |
| <i>Chair</i> | Task Force on Treatment Guidelines | 2021-2022 |
| Member | Certification Affairs Committee | 2019-2020 |
| Member | Best Poster (Overall) Judge Panel, Annual Meeting | 2018 |
| Member | Subject Matter Expert for Pharmacotherapy Standard Setting Panel | 2017 |
| Member | Publications Committee | 2012-2013 |
| Member | Membership Committee | 2009-2010 |
| Volunteer | Student Curriculum Vitae Review Service | 2008-2015 |

ACCP Ambulatory Care Practice & Research Network

| | | |
|--------|------------------------------------|----------------------|
| Member | Budget and Finance Committee | 2019-2020 |
| Member | Scholarly Activities Committee | 2017-2018 |
| Member | Nominations Committee | 2016-2017, 2008-2009 |
| Member | Education Committee | 2016-2017 |
| Member | Research Process Committee | 2015-2016 |
| Member | Research and Scholarship Committee | 2013-2015 |
| Member | Communications Committee | 2007-2008 |

ACCP Cardiology Practice & Research Network

| | | |
|--------------------|---|--------------|
| Member | Nominations Committee | 2024-Present |
| <i>Chair</i> | Cardiology Practice & Research Network | 2020-2021 |
| <i>Chair</i> | Programming Committee | 2020-2021 |
| <i>Chair-Elect</i> | Cardiology Practice & Research Network | 2019-2020 |
| <i>Co-Chair</i> | Research and Scholarship Committee | 2018-2019 |
| Member | Research and Scholarship Committee | 2017-2018 |
| <i>Chair</i> | Communications and Social Media Committee | 2015-2016 |

American College of Cardiology (ACC)

| | | |
|-----------------|--|--------------|
| Member | Chronic Coronary Disease Guideline Dissemination Work Group | 2023 |
| Member | Clinical Policy Approval Committee | 2022-Present |
| <i>Co-Chair</i> | Dyslipidemia Work Group, Prevention Council | 2018-2024 |
| Member | Scientific Sessions Programming Committee, Prevention Section | 2021-2024 |
| Member | Prevention of Cardiovascular Disease Section Leadership Council | 2021-2024 |
| <i>Elected</i> | Cardiovascular Team Chapter Representative, Virginia State Chapter | 2021-2024 |
| Member | PINNACLE/Diabetes Registry Research & Publications Subcommittee | 2019-2022 |
| Member | ACC/AHA Joint Committee on Clinical Practice Guidelines | 2019-2020 |
| Member | Member Well Being Work Group | 2019-2020 |
| Member | Membership Committee | 2018-2021 |
| Member | Hypertension Work Group | 2017-Present |
| <i>Chair</i> | Cardiovascular Team Section Membership Work Group | 2015-2021 |
| Member | Credentialing and Member Services Committee | 2015-2021 |
| Member | Diabetes/Cardiometabolic Work Group | 2014-Present |
| Member | Cardiac Care Team Committee, Virginia State Chapter | 2012-2024 |

National Lipid Association (NLA)

| | | |
|--------|--------------------|--------------|
| Member | Advocacy Committee | 2020-Present |
|--------|--------------------|--------------|

| | | |
|------------------------|---|--------------|
| <i>Co-Chair</i> | Scientific Statements Committee | 2020-Present |
| <i>President</i> | Southeast Lipid Association (SELA) Regional Chapter Board | 2020-2021 |
| <i>President-Elect</i> | Southeast Lipid Association (SELA) Regional Chapter Board | 2019-2020 |
| Member | 2018 Cholesterol Guideline Dissemination Task Force | 2018-2019 |
| <i>Treasurer</i> | Southeast Lipid Association (SELA) Regional Chapter Board | 2018-2019 |
| Member | Finance Committee | 2018-2019 |
| Member | Dues Task Force | 2017-2018 |
| <i>Co-Chair</i> | Social Media Committee | 2017-2020 |
| <i>Co-Chair</i> | Interprofessional Continuing Education Committee | 2017-2019 |
| <i>Secretary</i> | Southeast Lipid Association (SELA) Regional Chapter Board | 2017-2018 |
| Member | Scientific Sessions Meeting Planning Committee | 2016-2017 |
| Member | Publications Committee | 2015-2016 |
| <i>At-Large Member</i> | Southeast Lipid Association (SELA) Regional Chapter Board | 2014-2016 |
| Member | Patient Adherence Subcommittee | 2012-2013 |

Accreditation Council for Clinical Lipidology (merged with the American Board of Clinical Lipidology in Sept 2022)

| | | |
|------------------------|--|-----------|
| <i>President</i> | Board of Governors Executive Committee | 2021-2022 |
| <i>Vice-President</i> | Board of Governors Executive Committee | 2019-2021 |
| <i>Treasurer</i> | Board of Governors Executive Committee | 2018-2019 |
| <i>At-Large Member</i> | Board of Governors Executive Committee | 2015-2018 |

American Heart Association (AHA)

| | | |
|------------|--|--------------|
| Faculty | Workgroup on Assessing the Benefits of GLP-1 RAs for CV Risk Reduction | 2022-2023 |
| Member | Clinical Programming Subcommittee, Council on Hypertension | 2020-Present |
| Co-Captain | Richmond Heart Walk | 2015, 2016 |

UNIVERSITY, SCHOOL AND DEPARTMENT LEADERSHIP AND SERVICE ACTIVITIES

Virginia Commonwealth University

| | | |
|-----------------------|---|-----------|
| <i>Elected Member</i> | Faculty Senate | 2017-2020 |
| | Faculty Affairs Committee | 2019-2020 |
| | Academic and Professional Status Committee | 2017-2019 |
| Member | Real World Experience Steering Subcommittee | 2017 |
| <i>Elected Member</i> | University Council | 2014-2016 |

VCU Health System

| | | |
|----------------|--|-----------|
| Member | Search Committee, Preventive Cardiologist | 2023 |
| <i>Co-Lead</i> | Diabetes Care Model Redesign | 2018-2020 |
| Member | Vision by Design: Clinical Delivery Model Work Group | 2018 |
| Member | Collaborative Practice Work Group | 2016 |

Virginia Commonwealth University School of Pharmacy

| | | |
|--------------|--|--------------|
| Member | Director of Communications Search Committee | 2023 |
| Member | Expedited Tenure Review Committee for KC Ogbonna, PharmD | 2023 |
| Member | Dean Search Committee | 2022 |
| Member | Executive Committee | 2021-Present |
| Member | Academic Integrity Task Force | 2021-2022 |
| <i>Chair</i> | Outcomes and Assessment Committee | 2020-2021 |
| Member | Next Generation Pharmacist Task Force | 2019-2022 |
| Member | Academic Performance Committee | 2018-2019 |
| Member | Curriculum Committee | 2018-2020 |
| Member | Diversity Committee | 2018-2019 |

| | | |
|-----------------------|---|-----------|
| Member | Search Committee, Associate Dean for the Office of Experiential Education | 2017 |
| Member | Strategic PharmD Recruitment Task Force | 2016 |
| <i>Chair</i> | PharmD Admissions Committee | 2015-2017 |
| | Member | 2013-2017 |
| <i>Elected Member</i> | Promotion and Tenure Guidelines Committee | 2013-2015 |

Department of Pharmacotherapy & Outcomes Science

| | | |
|--------------|---|-----------------|
| Member | Collegiality Committee | 2023-Present |
| <i>Chair</i> | P&T Review Committee for John Bucheit, PharmD | 2020 |
| <i>Chair</i> | Search Committees for Oncology and Ambulatory Care faculty | 2019 |
| Member | Entrustable Professional Activities Work Group | 2017-2019 |
| Member | Search Committee, Health Services and Outcomes Science faculty | 2016, 2017-2018 |
| <i>Chair</i> | Search Committees for Ambulatory Care, Pediatrics, and Psychiatry faculty | 2017 |
| Member | Search Committee for Ambulatory Care | 2015 |
| Member | Service-Learning Subcommittee | 2014-2015 |
| Member | Student Mentoring and Advising Committee | 2013-2015 |

LICENSURES AND CERTIFICATIONS

| | |
|--|--------------|
| Certified Lifestyle Coach, National Diabetes Prevention Program | 2019 |
| Board Certified Ambulatory Care Pharmacist (BCACP) | 2016-Present |
| Clinical Lipid Specialist (CLS) | 2012-Present |
| Registered Pharmacist, Virginia (#0202211090) | 2011-Present |
| Certified Diabetes Care and Education Specialist (CDCES) | 2009-2024 |
| Clinical Pharmacist Practitioner (CPP), North Carolina (#0070-00174) | 2009-2011 |
| Board Certified Pharmacotherapy Specialist (BCPS) | 2007-2021 |
| Registered Pharmacist, North Carolina (#18289) | 2006-Present |

ACTIVE PROFESSIONAL MEMBERSHIPS

| | |
|--|---------------|
| American Pharmacists Association (APhA) | 2017-Present |
| Virginia Pharmacists Association (VPhA) | 2016-Present |
| American Heart Association (AHA) | 2015-Present |
| American Association of Colleges of Pharmacy (AACP) | 2012-Present |
| American College of Cardiology (ACC) | 2012-Present |
| National Lipid Association (NLA) | 2006-Present |
| American College of Clinical Pharmacy (ACCP) | 2005-Present |
| Campbell University Pharmacy Alumni Association | 2005-Present |
| Kappa Psi Pharmaceutical Fraternity, <i>Delta Lambda</i> Chapter | Inducted 2002 |